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Osteoarthritis is the leading cause of morbidity world-wide. Articular cartilage has limited 
regenerative potential and effective disease-modifying treatments for osteoarthritis are lacking. 
Hence, tissue engineering strategies to enhance cartilage repair potential are widely investigated. 
Adeno-associated virus (AAV) is a promising gene vector for articular cartilage and has already 
been used in clinical trials. We hypothesized that gene delivery of bioactive molecules to 
articular joints using AAV is efficacious to promote joint restoration. In the first two parts of the 
study, we showed persistent, localized, and controllable transgene expression within intact and 
injured joints following a single intra-articular injection of AAV. Most of the transduction 
occurred in the intra-articular soft tissues for intact joints and when the AAV was injected prior 
to joint injury, whereas some cartilage transduction but limited soft tissue transduction was seen 
when the AAV was injected following joint injury. Doxycycline was used as an induction agent 
of the AAV-mediated transgene expression. In the third part of the study, doxycycline was 
shown to have matrix-metalloproteinase-13 suppressing function during mesenchymal stem cell 
(MSC) chondrogenesis as well as in vivo cartilage repair. This supports potential use of 
doxycycline either alone or in gene therapy applications to improve cartilage repair. In the fourth 
part of the study, we optimized native biomaterial fibrin glue (FG) for its function as an AAV-
releasing scaffold for tissue engineering applications. Bioactive AAV from diluted FG showed 
 iv 
improved release, transduction efficiency, and chondrogenic effect on MSC. Lastly, AAVs 
encoding for anabolic and/or anti-inflammatory factors were explored to enhance MSC 
chondrogenesis in an inflammatory milieu. The MSCs transduced with AAV-interleukin-1 
receptor antagonist (IRAP), but not AAV-transforming growth factor (TGF)-β1, resulted in 
improved chondrogenic potential. In conclusion, various aspects of AAV-mediated joint 
restoration approaches were investigated, from characterization of AAV delivery by direct 
injection or with the use of FG, to therapeutic applications with doxycycline, AAV-IRAP, and 
AAV-TGF-β1. These results support continued investigations of therapeutic potential of AAV 
for safe, localized, and controlled delivery of bioactive substances to promote joint restoration, 
which may delay/prevent the onset of debilitating osteoarthritis. 
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1.0  INTRODUCTION: OSTEOARTHRITIS 
Osteoarthritis (OA) is the most common type of arthritis in the world and the single largest cause 
of disability (1, 2). According to the World Health Organization (WHO), OA is among the top 
10 conditions representing a global disease burden (3). It affects nearly 27 million people and 
costs almost $128 billion per year in medical care and indirect expenses in the US alone (4, 5). 
OA is symptomatically characterized by joint pain, tenderness, occasional effusions, deformity, 
and eventually loss of joint function with restrictions of motion (6). Clinical signs of OA include 
progressive degeneration of articular cartilage, which leads to fibrillation, ulceration, and joint 
space narrowing. Pathophysiology of OA is multi-factorial, but believed to be a combination of 
genetic, mechanical, and biochemical factors (7). It is traditionally regarded to result from “wear 
and tear” of the joint and hence associated with aging and obesity (8, 9). However, concerns with 
subjects with high physical activity, such as high impact sports athletes, and their risk of 
developing OA are also high (10, 11). Many studies have found a link between the development 
of OA and a history of participation in sports at an elite or professional level, especially for 
soccer, hockey, American football, and tennis (12). 
 1 
1.1 ARTICULAR CARTILAGE JOINT 
1.1.1 Articular cartilage joint in physiology 
The articular surface plays an essential role of allowing smooth transmission of force between 
two bones, thereby permitting painless movements of the joint (13). Articular cartilage is an 
avascular, aneural, and alymphatic tissue with a sparse population of chondrocytes embedded 
within a highly organized, dense extracellular matrix (ECM) (14). The mesenchymal cell-derived 
chondrocytes are the single cell type within the cartilage, and they maintain the homeostasis of 
the extensive framework of ECM via the synthesis of various anabolic and catabolic factors. The 
ECM is primarily composed of water, collagen type II (col-II), and aggrecan, which is a large 
aggregating proteoglycan that is highly hydrated due to the negative charge density of its sulfated 
glycosaminoglycan (GAG) (15). The col-II provides tensile strength while aggrecan allows the 
cartilage to resist compressive load and provides a friction-free articulating surface. The 
catabolic factors involved in cartilage homeostasis include matrix metalloproteinases (MMPs) 
that degrade collagens, and aggrecanases, such as a disintegrin-like and metalloproteinase with 
thrombospondin motif (ADAMTSs), which degrade aggrecans (14). With these compositions, 
the articular cartilage is a fluid-rich structure that functions in load-bearing via controlling the 
fluid movement in order to disperse the load/weight throughout the cartilage and to the 
underlying bone. As well, joint movement facilitates synovial fluid circulation and nutrient 
delivery to cartilage. However, due to the limited intrinsic capacity for self-repair, articular 
cartilage injuries due to trauma or degenerative inevitably progress to OA (16).  
In addition to articular cartilage, there are number of soft-tissue structures that are 
integral components of the joint. The anterior cruciate ligament (ACL) and menisci are the two 
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most relevant structures for the knee joint, as they are essential for joint stability and are 
commonly injured in the general population as well as in athletes (17). ACL connects the femur 
to tibia and is essential for the normal motion and stability of knee joints (18). It mainly consists 
of fibroblasts and ECM composed of non-parallel collagen types I and III fibers with multiple 
fascicles and is surrounded by synovium (18-20). ACL also contains small amounts of 
proteoglycans and glycoproteins (20). There are two bundles to the ACL, anteromedial and 
posterolateral, respective of their position on the tibia, and limits the forward motion of the tibia 
(21). ACL, alike articular cartilage, has a limited capacity to heal and regenerate after injury due 
to poor vascularity (22). Menisci are a pair of wedge-shaped semilunar fibrocartilages that are 
interposed between the femoral condyles and tibial plateaus of the knee joint (23). They function 
to correct the incongruency between these two articular cartilage surfaces, increasing the contact 
area in the femorotibial joint and reducing the stresses on tibial cartilage. Additional roles serves 
by menisci are shock absorption, stability enhancement, and lubrication (24). Molecular 
compositions of the menisci are mainly collagen type I (col-I), and small portions of collagens 
type II, III, V, and VI (25). Menisci also contain proteoglycan at a lesser degree than hyaline 
cartilage. 
1.1.2 Articular cartilage joint in pathology 
OA involves all joint components: cartilage, synovial membrane/synovium, and subchondral 
bone. During the OA pathogenesis, slow focal destruction of articular cartilage leads to a 
roughening and thinning of the weight-bearing regions of the articular surface, resulting in 
progressive immobility and pain (26). The process begins with the disruption of the cartilage 
cell-matrix interactions, with the alteration of matrix molecular structure and composition and 
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the loss of aggrecans. Inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis 
factor (TNF), and synovial inflammation have also been implicated as important mediators of the 
OA progression. These inflammatory cytokines upregulate expressions of MMPs and 
ADAMTSs (14). They also stimulate the chondrocytes to proliferate and synthesis more matrix 
components in an attempt to heal the articular cartilage. However, the chondrocytes’ proliferative 
potential and ECM synthesis capacity declines with time and age (27). The synovium is also 
capable of accelerating the articular cartilage degradation by degenerating soluble aggrecanases 
and inflammatory cytokines (15, 28). The col-II and aggrecan breakdown products have been 
shown to accumulate in the cartilage ECM as well as the synovial fluid during the OA process. 
Therefore, with progressive joint degeneration, the anabolic response eventually becomes 
overwhelmed by the catabolic activities, leading to progressive thinning of articular cartilage and 
to OA (14). 
Indirect cartilage injury and subsequent arthritis development due to joint instability 
induced by damaging the extra-cartilage soft tissue structure is also a common pathological 
process for the knee joint. Both ACL and menisci injuries have been shown to be followed by 
arthritic changes of the knees (29). In addition to the initial high force that damages intra-
articular structures involved in the trauma, the ACL and menisci ruptures initiate a cascade of 
pathogenic processes in the acute phase that can lead to the development of OA in itself (17, 30). 
In addition to acute effects, the lack of a functionally normal ACL or menisci leads to chronic 
changes in the static and dynamic loading of the knee and increase forces on the cartilage and 
other joint structures. Consequently, additional damages commonly occur in the ACL and/or 
menisci-injured knees, further contributing to initiation and progression of OA development 
(31, 32). 
 4 
1.2 CURRENT TREATMENTS AND LIMITATIONS 
Clinical strategies for management of cartilage pathology have evolved from primarily palliative 
methods to treat early disease until joint replacement for end-stage disease, toward more biologic, 
joint-conserving measures. These include cartilage reconstruction as in osteochondral graft 
transplantation (33), and cartilage repair as in bone marrow (BM) stimulation (34, 35), 
autologous chondrocyte implantation (36), or stem cell implantation (37). However, results of 
cartilage repair procedures have been equivocal, and no single approach has been shown to be 
superior (38, 39). Therefore, an important strategy for cartilage repair and tissue engineering is 
on investigating utilization of bioactive factors and biodegradable scaffolds to promote local, 
recruited, or transplanted cell proliferation and differentiation within cartilage wounds. Despite 
the promising results of in vitro growth factor application, in vivo application has not been as 
successful due to the short half-life of these growth factors and the need for high repetitive 
dosing as well as a costly purification process. 
1.3 TISSUE ENGINEERING AND GENE THERAPY FOR ARTICULAR 
CARTILAGE RESTORATION 
1.3.1 Adeno-associated virus and gene therapy 
Gene therapy can overcome the obstacles of short half-life, need for high repetitive dosing, and 
costly purification process associated with growth factor applications by delivery genes that 
encode chondrogenic growth factors or inhibitors of cartilage catabolites in various vector 
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constructs. This also provides for a local delivery system that drives the expression of therapeutic 
molecules over an extended period and overcome the need for repeated administrations or 
interventions. Gene carriers include plasmids, non-viral vectors, and viral vectors. Although 
plasmids and non-viral vectors are less toxic, less immunogenic, and easier to prepare, their gene 
delivery efficiencies are significantly lower compared to viral vectors (40). Hence, viral vectors 
are currently considered the most effective agents for in vivo gene transfer (41). 
Viral vectors that have been used in the pre-clinical setting include adenovirus, adeno-
associated virus (AAV) (42), and lentivirus (43). Many delivery vehicles can successfully target 
synovium and other soft tissues surrounding the articular cartilage (44-46). However, cartilage is 
particularly challenging for any type of transportation due to its highly impermeable and 
negatively charged ECM. 
 AAV is derived from an endemic, non-pathogenic parvovirus. It has the following 
advantages over other viruses: sustained transgene expression over longer period, reduced 
potential for host immune response, and the capacity to transduce both dividing and non-dividing 
cells (47). After transduction, the viral genome translocates into the target cell nucleus, and the 
DNA polymerase generates the transducing episome. Numerous serotypes of AAV have been 
identified, each having different preferential targets. Among the different serotypes, AAV 
serotype 2 (AAV2) is considered to have the best defined safety profile as it has already been 
used in clinical trials (48). 
There are three general approaches for cartilage viral gene therapy applications: direct, 
indirect, and hybrid. The direct method involves the injection of viral vectors directly into the 
articular joint space to transducer local cells (47). The indirect approach involves the use of 
genetically modified cells (42), and/or biodegradable scaffolds that release genetically modified 
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cells (49, 50). This leads to the site-specific release of bioactive molecules important in tissue 
regeneration, though temporary. In addition, this approach requires ex vivo manipulation of 
cultured cells, which faces high barriers with respect to clinical translation. The third hybrid 
approach involves implantation of biodegradable scaffolds embedded with genetic materials 
(51, 52), leading to direct and localized in situ delivery of bioactive vectors to the host cells in 
proximity to the scaffold, as well as the sustained expression of the transgene.  
1.3.2 Scaffold Biomaterial: Fibrin Glue 
Fibrin glue (FG) is a natural substance available for human use clinically as a commercial 
product or readily prepared from plasma for autologous applications (53). These properties mean 
that laboratory findings may be more readily translated into potential human clinical applications 
than similar findings with synthetic polymers. Despite being widely used in clinical surgical 
practice as an adhesive and sealant for hemostasis (54), only in recent years has the ability of FG 
to act as a delivery scaffold received attention (55). Besides being commercially available for 
sterile applications, it is non-immunogenic, biodegradable, and malleable so that it can be 
molded into irregular tissue defects. All of these advantages make FG an appealing scaffold for 
pre-clinical translational cartilage tissue engineering applications.  
1.3.3 Cell types used in joint restoration 
Tissue engineering strategies for cartilage repair with autologous cell sources mostly involves 
use of chondrocytes isolate from cartilage (56), or mesenchymal stem cells (MSCs) from bone 
marrow (57), fat (58), and muscle (59). While autologous chondrocytes has good 
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biocompatibility and better suited to produce cartilage tissue compared to other cell types, donor-
site morbidity and need for initial arthroscopic surgery is severely limiting. New clinical 
approaches in tissue engineering or regenerative medicine heavily utilize stem cells. Since 
chondrocytes are of mesodermal lineage, MSCs are more appropriate than epidermal or 
endodermal stem cells. Extraction of MSCs is also associated with less donor-site morbidity and 
does not disrupt normal healthy cartilage tissue.  
Clinically, some level of variability has been observed from outcomes of microfracture, 
that involves MSC chondrogenesis (57). As well, most of the repair tissues have been 
characteristics of fibrocartilage versus hyaline cartilage. A potential approach to overcome the 
decreased differentiation ability of certain MSC populations and enhance hyaline cartilage 
formation is the addition of growth factors. Hence, supplementation of additional bioactive 
factors, such as anabolic or anti-catabolic factors, may enhance the results of these MSC-based 
cell therapies for cartilage restoration 
1.3.4  Bioactive factors in joint restoration 
TβR-II
Cytoplasm
TGF-β
R-I
Smad 2/3
Smad 2/3 P
Smad 4
Nucleus
Smad 2/3 PSmad 2/3 P
Smad 4
Smad 7
Smad 2/3 PSmad 2/3 P
Smad 4
Figure 1-1: TGF-β – Smad Signaling Pathway 
Adapted from Piek, et al. (60) 
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Treatment strategies based on the use of bone-marrow derived cartilage progenitor stem cells, 
such as MSCs, and growth factors have been extensively studied using well-established in vitro 
chondrogenic assays and in vivo animal models (61). Transforming growth factor-β (TGF-β) is 
the most extensively examined anabolic growth factor for hMSC induction into chondrogenic 
phenotype in vitro (57, 62), especially the TGF-β1 isoform (63). Relevant TGF-β1 signaling 
pathway (Fig. 1-1) include TGF-β1 binding to its type II receptor (TGF-β-R-II), which then 
forms a complex with the type I TGF-β receptor (64). Upon the receptor activation, intracellular 
signaling molecule Smad2 or Smad3 gets phosphorylated, forms a complex with Smad4, and the 
complex then translocates to the nucleus to function as a transcription factor. Via this mechanism, 
TGF-β1 stimulates collagen-II and proteoglycan expressions in MSCs (65). Smad7 inhibits 
Smad2 and Smad3 phosphorylation and prevents further signaling. In addition to its anabolic 
functions, TGF-β1 also decreases the catabolic activity of inflammatory cytokines, such as IL-1, 
in vitro and in vivo (64). However, a number of deleterious side effects have been associated 
with uncontrolled high-dose TGF-β1 administration in vivo, including synovial fibrosis and 
osteophyte formation (61, 66, 67). These side effects have been shown to be blocked when 
Smad7 was intracellularly overexpressed in the synovial lining while maintaining TGF-β1 
induced cartilage repair effects (68).  
On the catabolic side, IL-1β and TNF-α are pro-inflammatory cytokines that activate the 
nuclear factor kappa-light chain enhancer of activated B cells (NF-κB) pathway, induce 
destructive processes in multiple cell types in the joint space, and thus play a critical role in the 
progression of OA (26, 69). These cytokines accelerate the switching of the anabolic to catabolic 
states of the cartilage, and it has been shown that each of their stimulation increases the 
expression of catabolic enzymes, such as ADAMTS-5 (69, 70) and MMP-13 (71). As well, IL-
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1β and TNF-α have been shown to inhibit TGF-β1-mediated hMSC chondrogenesis (71). 
Previous animal studies showed that TNF is a potent pro-inflammatory mediator and IL-1 a 
potent cartilage catabolic mediator (72). Arthritis induced by TNF-overexpression was 
completely blocked by antibodies targeting IL-1 receptor, suggesting that IL-1 is the pivotal 
downstream mediator in arthritis. IL-1 receptor antagonist (IL-1Ra) is a small 20-25 kDa 
secreted protein that competitively inhibits IL-1 by binding to and preoccupying type I IL-1 
receptors, thus preventing IL-1 ligand-receptor interactions (73). It has no known agonist activity 
(74). However, although this strategy is straightforward, the efficacy is limited by the poor 
pharmacokinetics of the small molecule and the need for high dosing to fully occupy IL-1 
receptors for prolonged periods of time. 
1.4 PROJECT OBJECTIVES 
The central hypothesis of this project is to test the hypothesis that modulation of various anabolic 
and catabolic factors involved in mesenchymal stem cell (MSC) chondrogenesis via adeno-
associated virus (AAV) will enhance the outcomes of joint restoration. 
1.4.1 Objective #1: To test the hypothesis that the transgene expression in articular 
cartilage joint is localized, persistent, and controllable following a single intra-
articular injection of adeno-associated virus 
Adeno-associated virus (AAV) is a promising delivery vehicle for articular cartilage. Most 
simple method to deliver the genetic material for cartilage viral gene therapy applications is by 
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direct injection for the resident cells within the joint to produce the therapeutic factor. 
Knowledge of the duration of transgene expression is critically important to develop efficient 
therapies. As well, while long-term transgene expression may be critical for disease treatment, it 
may not be ideal for cartilage repair strategies, where a growth factor may only be needed for a 
limited time period. In cases where a growth factor is needed for a specific period of time, it may 
be advantageous to use an inducible gene expression system, where the transgene expression can 
be controlled pharmacologically by oral administration of the inducing agent. The tetracycline-
inducible gene regulation system has been efficient both in vitro and in vivo (75-77). 
Doxycycline, an analog of tetracycline, is widely accepted as an inducer due to its safe use in 
humans (78). 
In this objective, AAV-mediated transgene persistence, duration, and controllability will 
be studied in intact rat diarthrodial joint using a reporter gene luciferase. Also, since the intact 
and undamaged articular cartilage is unlikely to require treatment, AAV transduction and 
transgene expression profiles in rat models of articular joint damage will provide invaluable 
information to improve gene therapy strategies, as they will more closely mimic the disease 
environment. Two different AAV injection time points, pre- and post-injury, will be investigated 
on osteochondral defect and anterior cruciate ligament transection models of joint damage. 
1.4.2 Objective #2: To test the hypothesis that doxycycline reduces MMP, improves 
chondrogenesis of human bone marrow derived mesenchymal stem cells (MSC), 
and does not adversely affect repair of osteochondral defect (OCD) 
New strategies to improve repair tissue quality after bone marrow cell based procedures such as 
microfracture may reduce later development of osteoarthritis (OA). Doxycycline can be used to 
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control intra-articular transgene expression and has been shown to reduce matrix 
metalloproteinases (MMP) and OA disease progression. In this study, MSCs will be cultured in 
chondrogenic media with either 0, 1 or 2-μg/mL doxycycline to assess the doxycycline effect on 
chondrogenic differentiation. Rats will be treated with or without oral doxycycline following 
osteochondral defect surgeries to assess the doxycycline effect on cartilage repair. These studies 
will evaluate the potential use of doxycycline either alone or in combination with AAV gene 
therapy applications to improve cartilage repair and delay OA.  
1.4.3 Objective #3: To test the hypothesis that fibrin glue concentration alters the 
adeno-associated virus-release profile, which affects adeno-associated virus-
bioavailability 
Use of biodegradable scaffolds embedded with AAV can lead to direct and localized in situ 
delivery of bioactive vectors to the host cells in close proximity to the scaffold. Although 
numerous novel synthetic and natural polymers have been investigated for cartilage tissue 
engineering studies, usage of an FDA-approved and autologous biomaterial as an AAV-releasing 
scaffold can accelerate the transition of basic science research into human clinical studies. Fibrin 
glue (FG) is a biomaterial widely used in clinical practice and tissue engineering applications. 
Nonetheless, FG formulation for AAV delivery has not been optimized. FG hydrogels containing 
varying fibrinogen concentrations will be characterized for its function as an AAV-releasing 
scaffold in vitro. Specifically, alterations in FG scaffold microstructure via different dilutions 
and its effect on AAV-release capacity will be characterized. As well, usage of biodegradable FG 
scaffold for release and delivery of bioactive AAVs to hMSCs will be done by assaying for the 
induction of cartilage specific genes. 
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1.4.4 Objective #4: To test the hypothesis that chondrogenic potential of human 
mesenchymal stem cells will be enhanced by using adeno-associated virus 
encoding for anabolic factors and/or anti-catabolic factors 
Anabolic growth factors have been extensively studied for hMSC chondrogenesis and cartilage 
repair (16, 42, 57, 65, 79). However, the catabolic side of the balance, which is increasingly 
recognized to be important, warrants additional investigation. Interleukin-1 (IL-1) is the pivotal 
inflammatory cytokine in articular cartilage pathologies, with its levels greatly upregulated 
within the joint in disease processes (71). Furthermore, it has been shown the IL-1β inhibits 
hMSC chondrogenesis (71, 80). Therefore, anti-IL-1 strategy like IL-1 receptor antagonist 
protein (IL-1Ra or IRAP), which competitively inhibits IL-1, holds further therapeutic potential 
(81). Transforming growth factor-β (TGF-β) is the most extensively examined anabolic growth 
factor for hMSC induction into chondrogenic phenotype and its use in chondrogenic media has 
long been established (61, 62). However, it has also been shown to blunt cytokine-mediated 
inhibition of hMSC chondrogenesis (71). As a basis to apply IRAP and TGF-β1 anti-
inflammatory strategies in clinical MSC-mediated cartilage repair, AAV-IRAP transduced 
hMSCs and AAV-TGF-β1 transduced hMSCs will be investigated for their chondrogenic 
differentiation in an inflammatory environment. 
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2.0  SINGLE INTRA-ARTICULAR INJECTION OF ADENO-ASSOCIATED VIRUS 
RESULTS IN STABLE AND CONTROLLABLE IN VIVO TRANSGENE EXPRESSION 
IN NORMAL RAT KNEES 
2.1 INTRODUCTION 
Prevention of articular cartilage degradation or treatment of its damage in arthritis remains 
challenging due to the limited self-repair potential of articular cartilage. Currently, no therapeutic 
methods exist for complete re-establishment of cartilage function. Delivery of therapeutic agents 
that could promote articular cartilage repair or prevent its further degradation once damaged is an 
attractive therapeutic option. Protein biologics can be delivered systemically, or locally by direct 
injection or through polymer based delivery systems (82). However, due to the short half-life of 
proteins, administration of supra-physiological doses and/or repeated delivery are often 
necessary, significantly increasing the cost of these approaches. An attractive alternative is to 
deliver the genetic information to cells within the joints and engineer them to produce the 
therapeutic protein in situ. 
Naked DNA, retrovirus, adenovirus, and herpes virus-based vectors have been explored 
for gene transduction in vivo; however, most were rendered suboptimal due to safety, efficacy, 
and duration issues. Recombinant adeno-associated virus (AAV) derived from an endemic and 
non-pathogenic parvovirus is emerging as a promising delivery vehicle for musculoskeletal 
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tissues, with the advantages of sustained transgene expression, reduced potential for host 
immune response, and the capacity to transducer both dividing and non-dividing cells in vitro 
and in vivo (83). Different serotypes of AAV exist, each having different preferential targets 
(83, 84). AAV5 has better transduction efficacy in rodent arthritic joints; however, AAV2 is 
currently used in human clinical trials for arthritis (85-88).  
Many studies have genetically engineered cells ex vivo for implantation in vivo. Although 
this has led to cartilage repair in animal models (42, 89-92), culturing cells ex vivo prolongs the 
time before treatment and is also very expensive in a clinical setting. An alternative method 
would be direct injection and rely on the cells within the joint to produce the therapeutic factor. 
AAV vectors have a strong tropism for synoviocytes in vitro (93-96). However, few studies have 
identified the exact in vivo localization of the transgene, after intra-articular injection of AAV 
(44, 46, 79, 97-99). It is important to identify which cells or tissues are infected by AAV after 
intra-articular injection and to use this information to develop optimal treatment strategies for 
intra-articular disease processes such as inflammatory and degenerative arthritis.  
Knowledge of the duration of transgene expression is also important to develop efficient 
therapies. It has been reported that parkinsonian nonhuman primates having received AAV2 
encoding human L-amino acid decarboxylase (L-DOPA) into their brains were still expressing 
the transgene after 8 years (100). AAV-mediated erythropoietin delivery to rhesus monkey 
skeletal muscle has led to transgene expression for more than 6 years (77). Long-term transgene 
expression may be critical for disease treatment, but may not be ideal for cartilage repair 
strategies, where a growth factor may only be advantageous to use an inducible gene expression 
system, where the transgene expression can be controlled pharmacologically by oral 
administration of the inducing agent. The tetracycline-inducible gene regulation system has been 
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efficient both in vitro and in vivo (75-77). Doxycycline (Dox), an analog of tetracycline, is 
widely accepted as an inducer due to its safe use in humans (78). Only few studies have 
investigated the use of an AAV-based tetracycline-inducible gene system in the knee joint after 
direct injection. 
Given the potential translational value of AAV for human clinical use, the aim of the 
present study was to investigate the presence, persistence, and ability to externally control 
transgene expression when using AAV2 delivered by a single intra-articular injection into the rat 
diarthrodial joint. The immunocompetent rat was chosen since it is a good animal model for 
future studies that will test the repair of articular cartilage, the prevention of its degradation, or 
the treatment of inflammatory arthritis by AAV-mediated gene therapy. 
2.2 METHODS 
2.2.1 AAV vector production 
Double-stranded serotype 2 AAV (AAV2) vectors were produced using the three-plasmid 
cotransfection method (101). Depending on the AAV2 vector being produced, the first plasmid 
used was either the AAV-cytomegalovirus (CMV)-Luc plasmid with the luciferase (Luc) gene 
driven by the CMV promoter, the AAV-CMV-enhanced green fluorescent protein (GFP) plasmid, 
the AAV-CMV-reverse-tetracycline-controlled transactivator (rtTA) plasmid, or the AAV-TRE-
Luc plasmid with the Luc gene driven by the tetracycline response element (TRE) promoter. The 
second plasmid used in the cotransfection was the pXX6 plasmid, which contains the helper 
genes from adenovirus, and the third plasmid was the pXX2, which supplies AAV2 rep protein 
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and capsid protein (101). Vector purification was performed as previously described and AAV 
genomic titers were determined by DNA dot-blot assay (101). 
2.2.2 In vitro infection of rat articular chondrocytes 
Primary rat articular chondrocytes were extracted from the tibial and femoral cartilage of 3-
month-old male Sprague Dawley rats. Cartilage samples were washed in phosphate buffered 
saline (PBS; Invitrogen) with 2% penicillin-streptomycin (pen/strep; Invitrogen). To digest the 
cartilage, thin shavings were incubated in 0.2% pronase (Calbiochem) solution in F-12 medium 
(Invitrogen) supplemented with 5% fetal bovine serum (FBS) and 1% pen/strep for 90 min in a 
dry 37°C incubator. This was followed by overnight digestion in 0.025% collagenase P (Roche 
Applied Science) in F-12 medium supplemented with 5% FBS and 1% pen/strep. Recovered 
chondrocytes were seeded as monolayers in a T-75 flask in 50% Dulbecco’s Modified Eagle 
medium/50% F-12 medium (DMEM/F-12; Invitrogen) supplemented with 10% FBS, and 1% 
pen/strep under normal growth conditions (37°C, 5% CO2). Cells were grown to passage four 
and plated onto 96-well plates at a density of 2.0 x 104 cells/cm2 in growth medium (DMEM/F-
12, 10% FBS, 1% pen/strep). On the following day, chondrocytes in plain DMEM/F-12 were 
infected with 3.2 x 105 vector genomes per cell (vg/cell) of AAV-CMV-GFP, AAV-CMV-Luc, 
or AAV-CMV-rtTA + AAV-TRE-Luc for 1 h, after which the medium was changed to growth 
medium. This dose was selected because it gave the greatest gene expression in an in vitro dose 
response study ranging from 4 x 104 – 3.2 x 105 vg/cell (data not shown). After 2 days, cells 
infected with AAV-TRE-Luc were stimulated with Dox at concentrations of 0, 1, or 2 μg/mL for 
36 h. Luciferase transgene expression was measured 4 days post-transduction by adding 50 μL of 
luciferin (30 mg/mL; D-Luciferin Firefly, Caliper Life Sciences) per well and imaging after 5 
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minutes with the IVIS® 200 optical imaging system (Xenogen Corp., Hopkinton, MA, USA). 
GFP signal was visualized on the same day using the epifluorescent Eclipse TE-2000U inverted 
microscopy (Nikon).  
2.2.3 Animal experiments 
All animal experiments were performed following a University of Pittsburgh Institutional 
Animal Care and Use Committee approved protocol. The study was divided into two parts. 
In the first study, nine male Sprague Dawley rats (3 months old) received a 50 μL intra-
articular injection containing 2.5 x 1010 vg of AAV-CMV-GFP or AAV-CMV-Luc into the right 
and left knee joint, respectively. For longitudinal evaluation of luciferase expression, rats were 
anesthetized with isoflurane inhalation, followed by a 50 μL intra-articular injection of luciferin 
(30 mg/mL). After 5 min, to allow proper distribution of luciferin, rats were placed in an IVIS® 
200 optical imaging system. Photon emissions in the region of interest were quantified using 
Living Image software v.3.0 (Xenogen Corp.), and bioluminescent flux was reported as 
photons/sec. Rats were imaged every other week for 4 months, and monthly thereafter, until 1 
year post-AAV injection. Rats were sacrificed at either 1 week (N = 1), 2 weeks (N = 2), 3 
months (N = 1), 4 months (N = 1), or 1 year (N = 4) after AAV injection. On the day of sacrifice, 
rats received an intraperitoneal injection of 100 μL of luciferin to determine whether any signal 
was present outside of the intra-articular space. They also received an intra-articular injection of 
luciferin and imaged as previously described. The joint was then opened to image the intra-
articular tissues. Tissues within the joint were also analyzed for GFP-positive cells using a 
fluorescent stereomicroscope (MVX-10 MacroView Systems, Olympus, Japan) equipped with a 
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DP71 camera (Olympus). All GFP images in Fig. 2-4 had the contrast increased by the same 
value in Adobe Photoshop to improve the GFP signal for print. 
In the second animal experiment, the right and left knees of four male Sprague Dawley 
rats (3 months old) were divided into experimental and control groups. In the right knee, each rat 
received a 50 μL intra-articular injection containing 2.5 x 1010 vg of AAV-TRE-Luc and 2.5 x 
1010 of AAV-CMV-rtTA. In the left knee, each rat received a 50 μL intra-articular injection 
containing 2.5 x 1010 vg of AAV-CMV-Luc and 2.5 x 1010 vg of AAV-CMV-rtTA, to have the 
same number of vg in both knees. To induce expression of luciferase in the right knee joint 
(injected with AAV-TRE-Luc), rats were administered drinking water containing Dox at a 
concentration of 2 mg/mL for 7 days, followed by its removal. To ensure fresh supply, the water 
was replaced every day and protected from light with amber drinking bottles. Rats were imaged 
twice a week as described above. Addition of Dox to the drinking water was performed at 14 
days, 8 months, and 13 months post-AAV injection. 
2.2.4 Statistical analysis 
In vitro studies were repeated three times with 3 – 9 replicates. A representative experiment is 
shown in Fig. 2-1 (n = 9). In vivo studies were conducted and data observed using independent 
animals, with N = 4 – 8 for Fig. 2-2 due to animals being sacrificed at different time points 
during the study and N = 4 for Fig. 2-5. All data are represented as median and interquartile 
range boxplots with percentiles calculated using Tukey Hinge. The significant level used was p < 
0.05, unless otherwise noted. Assumptions of parametric data were tested for all data: normality 
of data distribution using Shapiro-Wilk test and homogeneity of variance using Levene’s test. 
For parametric data (Fig. 2-5), one-way analysis of variance (ANOVA) with post-hoc Tukey was 
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used. For non-parametric independent data (Fig. 2-1), a Kruskal-Wallis test and post-hoc pair-
wise Mann-Whitney U with a Bonferroni correction was used. P-values less than 0.008 (0.05/6 
total comparisons) were considered significant. For non-parametric data in the longitudinal study 
(Fig. 2-2), Friedman’s ANOVA test was used with the Wilcoxon test and a Bonferroni correction 
applied for post-hoc analysis of each consecutive time point. P-values less than 0.005 (0.05/10 
comparisons) were considered significant. Statistical evaluations were performed with SPSS 
software (IBM). 
2.3 RESULTS 
Figure 2-1: In vitro response of rat articular chondrocytes to AAV2 
Rat articular chondrocytes were infected with AAV-CMV-Luc or AAV-TRE-Luc, stimulated with Dox (0, 1, or 2 
μg/mL) for 36 h, and luciferase signal was detected. Upper panel: image of bioluminescence signal from the cells 
infected with (left to right) AAV-CMV-Luc, AAV-TRE-Luc (no Dox), AAV-TRE-Luc stimulated with 1 μg/mL 
Dox, and AAV-TRE-Luc stimulated with 2 μg/mL Dox. Lower panel: median and interquartile range of 
bioluminescence for the different cell groups. n = 9. *p < 0.001 for AAV-TRE-Luc: 1 μg/mL Dox vs AAV-TRE-
Luc and for AAV-TRE-Luc: 2μg/mL Dox vs AAV-TRE-Luc. #p < 0.001 for AAV-TRE-Luc: 1 μg/mL Dox vs 
AAV-CMV-Luc and for AAV-TRE-Luc: 2μg/mL Dox vs AAV-CMV-Luc. ▲p < 0.001 for AAV-TRE-Luc: 2 
μg/mL Dox vs AAV-TRE-Luc: 1 μg/mL Dox.
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2.3.1 In vitro response of rat articular chondrocytes to AAV2 vectors 
GFP expression was visualized in articular chondrocytes infected with AAV-CMV-GFP as early 
as 24 h post-infection (data not shown). Articular chondrocytes infected with AAV-CMV-Luc 
had luciferase expression (Fig. 2-1). Infection of articular chondrocytes with AAV-TRE-Luc led 
to weak bioluminescence when no Dox was added (Fig. 2-1, AAV-TRE-Luc). This signal was 
significantly increased when the cells were cultured with Dox at concentrations of 1 μg/mL and 2 
μg/mL for 36 h (Fig. 2-1, *p < 0.001 for AAV-TRE-Luc: 1 μg/mL Dox and AAV-TRE-Luc: 2 
μg/mL Dox compared to AAV-TRE-Luc). The bioluminescence observed in vitro with the 
AAV-TRE-Luc vector and addition of Dox was also greater than that obtained with the AAV-
CMV-Luc vector (Fig. 2-1, #p < 0.001 for AAV-TRE-Luc: 1 μg/mL Dox and AAV-TRE-Luc: 2 
μg/mL Dox compared to AAV-CMV-Luc). A significant difference was also observed between 
the two concentrations of Dox tested (Fig. 2-1, ▲p < 0.001 for AAV-TRE-Luc: 2 μg/mL Dox 
compared to AAV-TRE-Luc: 1 μg/mL Dox). 
2.3.2 Duration of in vivo transgene expression after a single intra-articular injection of 
AAV2 
The IVIS® 200 optical imaging system enables in vivo tracking of luciferase expression in the 
same rat knee joints over a 1 year period. Bioluminescence was visualized as early as 14 days 
after intra-articular injection of AAV-CMV-Luc and persisted in all animals for 1 year, the study 
end point. Figure 2-2A shows bioluminescent images from a representative animal at 14 days, 1 
month, 6 months, and 1 year after intra-articular injection of AAV-CMV-Luc. In all study 
animals, the luciferase signal remained constant throughout the duration of the study (Fig. 2-2B). 
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The contralateral AAV-CMV-GFP-injected knees did not show luciferase signal during the study. 
Intraperitoneal injection of luciferin and imaging before sacrifice also indicated that no luciferase 
signal was present outside the injected knee area. 
Figure 2-2: Duration of in vivo transgene expression after a single intra-articular injection of AAV-CMV-
Luc 
Transgene expression was observed and quantified using bioluminescence imaging to detect luciferase activity.  
(A) Bioluminescent images of the left knee joint of a representative rat at 14 days, 1 month, 6 months, and 1 year 
after a single intra-articular injection of AAV-CMV-Luc. (B) Median and interquartile range of bioluminescence 
observed in the left knee joint of all rats in the study over 1 year following intra-articular injection of AAV-CMV-
Luc. N = 4 – 8 rats (N = 8 at 14 days, N = 6 at 1 and 2 months, N = 5 at 3 months, and N = 4 from 4 months to 1 
year). No significant difference was observed between the different time points. 
2.3.3 Localization of in vivo transgene expression after a single intra-articular injection 
of AAV2 
To localize luciferase signal, knees were imaged intact (Fig. 2-3A) and after exposing the intra-
articular space (Fig. 2-3B). Bioluminescence was concentrated in two areas (Fig. 2-3B and C). 
The majority of the signal was found in the exposed infrapatellar fat pad area, with some signal 
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in the intra-articular space containing the ligaments and meniscus. No bioluminescence was 
observed in articular cartilage. 
 
Figure 2-3: Localization of in vivo luciferase expression after a single intra-articular injection of AAV-
CMV-Luc by using the IVIS optical imaging system 
(A) Luciferase was detected in the intact left knee joint. (B) Exposure of the intra-articular space of the same knee 
joint in (A) revealed that the luciferase signal was located in two major areas. (C) A higher magnification of (B) 
indicated that the signal was mainly found in the infrapatellar fat pad and in the soft tissues between the femur and 
tibia, such as the ligaments and meniscus.  
Tissues retrieved from the AAV-CMV-GFP-injected side provided more information on 
the localization of cells expressing the transgene. Abundant GFP-positive cells were found in 
soft tissues such as synovium, infrapatellar fat pad, and tissues within the intra-articular joint 
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space. Figure 2-4A shows a large area of GFP-positive cells within meniscus, while Figure 2-4B 
shows GFP-positive cells in soft tissues surrounding the tibial plateau. GFP-positive cells could 
be found when compared to soft tissues. As seen in Figure 2-4C, two small areas containing 
GFP-positive cells were found on the trochlear ridge of the femur. Large areas of GFP-positive 
cells in articular cartilage were not found in any of the study animals.  
2.3.4 Controlled in vivo transgene expression following a single intra-articular injection 
of AAV2 
Persistent luciferase expression was observed for the duration of the experiment, in all knee 
joints injected with AAV-CMV-Luc (Fig. 2-5A, B, and C). Intra-articular injection of AAV-
TRE-Luc led to a weak luciferase signal before addition of Dox to the drinking water of the rats 
(Fig. 2-5A). Fourteen days post-AAV injection, Dox was added to the drinking water and led to 
a significant increase in the luciferase signal after 7 days (Fig. 2-5B and D, median fold increase 
of 11.28 and interquartile range of 16.34 (twenty-fifth-percentile = 8.20, seventy-fifth-percentile 
= 19.46) and *p = 0.015 compared to Day 0: Dox (-)). Removal of Dox significantly decreased 
the signal 7 days later (Fig. 2-5C and D, #p = 0.023 compared to Day 7: Dox (+)). When 
measured 8 months post-AAV injection, addition of Dox to the drinking water of the rats for 7 
days increased luciferase expression by a median fold increase of 4.31 and interquartile range of 
5.45 (twenty-fifth-percentile = 2.16, seventy-fifth-percentile = 6.04) and p = 0.099 compared to 
Day 0: Dox (-). The luciferase signal returned to pre-Dox values after the inducer had been 
removed for 7 days. The induction cycle performed 13 months after the initial injection of AAV 
also showed increased luciferase signal on the AAV-TRE-Luc side 7 days after addition of Dox 
to the drinking water (Fig. 2-5E, median fold increase of 38.43 and interquartile range of 32.46 
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Figure 2-4: GFP-positive cells in tissues harvested from the knee joint of rats injected with AAV-CMV-
GFP, imaged with a stereomicroscope 
(A) Brightfield image (left panel) of meniscal tissue with the area located within the square enlarged to show the 
GFP-positive cells (right panel). (B) Brightfield image (left panel) of tibial plateau. Area within the square is 
magnified in the right panel and shows GFP-positive cells within the soft tissue. (C) Brightfield image of the 
trochea (left panel). GFP-positive cells were sparse in articular cartilage. Two small areas with GFP-positive cells 
were found on the trochlear ridge in this animal (right panel).
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(twenty-fifth-percentile = 27.48, seventy-fifth-percentile = 54.90) and *p = 0.003 compared to 
Day 0: Dox (-)). Removal of Dox decreased the signal to baseline levels (Fig. 2-5E, #p = 0.016 
compared to Day 7: Dox (+)). 
Figure 2-5: Controlled in vivo transgene expression following a single intra-articular injection of AAV2 
 (A-C) Bioluminescent images of a representative rat that received AAV-TRE-Luc in the right knee and AAV-
CMV-Luc in the left knee 14 days prior. Images shown were taken (A) before addition of Dox to the drinking water 
(Day 0), (B) 7 days after Dox was added to the drinking water (Day 7) and (C) 7 days after Dox was removed from 
the drinking water (Day 14). Luciferase expression was stable in the knee joint injected with AAV-CMV-Luc, but 
varied with Dox administration in the knee joints injected with AAV-TRE-Luc. (D) Bioluminescence measured in 
the knee joint 14 days post-AAV-TRE-Luc injection. Bioluminescence is represented as a median fold increase over 
Day 0, when no Dox was present in the drinking water, and interquartile range. Luciferase expression increased with 
addition of Dox to the drinking water after 7 days (Day 7: Dox (+)). *p = 0.015 compared to Day 0: Dox (-). After 
removal of Dox from the drinking water for 7 days (Day 14: Dox (-)), the luciferase signal decreased. #p = 0.023 
compared to Day 7: Dox (+). (E) Median and interquartile range of bioluminescence measured 13 months post-
injection with AAV-TRE-Luc. Luciferase expression increased 7 days after Dox was present in the drinking water 
(Day 7: Dox (+)). *p = 0.003 compared to Day 0: Dox (-). Luciferase expression decreased 7 days after removal of 
Dox (Day 14: Dox (-)). #p = 0.016 compared to Day 7: Dox (+). N = 4 rats.
2.4 DISCUSSION 
Prevention of articular cartilage degradation or promotion of its repair in inflammatory and 
degenerative arthritis remains challenging. Therapeutic strategies that rely on the delivery of 
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growth factors to enhance repair or inhibitory molecules that would prevent degradation are of 
interest. Ideally, the therapeutic protein should be produced in situ, to obtain a persistent and 
stable concentration, thus limiting the need for purification processes, repeated injections, and 
supra-physiological doses, which are not cost effective. Gene therapy is a promising alternative 
to the delivery of therapeutic factors, as it provides the genetic material necessary for protein 
synthesis in situ. In this study, we analyzed important aspects for efficient intra-articular gene 
delivery. These included the persistence and localization of transgene expression after a single 
intra-articular injection of AAV2, as well as the ability to control the transgene expression over 
time when using an inducible AAV2 vector. 
Efficacy of AAV2 for in vitro chondrocyte transduction was evaluated using GFP and 
luciferase as reporter genes. In accordance with other studies on mice, rabbit, equine, and human 
chondrocytes (98, 102-104), rat articular chondrocytes were also capable of uptaking the AAV2 
vector and producing the transgene protein, suggesting that AAV2 could be used to infect rat 
chondrocytes in vivo. The ability to induce transgene expression with addition of Dox to the cell 
culture medium demonstrated the potential to control the timing of transgene expression. 
Studies in nonhuman primates indicate that administration of AAV to the brain leads to 
transgene expression for as long as 8 years (100), yet few studies have assessed the persistence 
of transgene expression after AAV administration to the rat knee joint past a few months 
(45, 79, 95, 99). Intra-articular injections into the rat stifle joint, while challenging, have 
previously been reported by our group and others (45, 46, 79, 105). Given this experience, we 
believe that AAV was delivered intra-articularly in this study, although it is possible that some 
leakage or partial extra-articular injection may have occurred. By using bioluminescence, the 
same animal could be imaged repeatedly, providing a clear profile of transgene persistence and 
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biodistribution. All animals had stable luciferase transgene expression for up to 1 year following 
intra-articular injection of AAV-CMV-Luc. A recent study employing recombinant lentivirus or 
adenovirus vectors did not observe such stable transgene expression in knees of 
immunocompetent rats (106). They observed strong transgene expression that diminished over a 
3-week period. Injection of the same vectors into athymic rats led to an initially high transgene 
expression, which decreased to 20% and remained at that level for 6 months (106). Prolonged 
transgene expression in the current study suggests lower immunogenicity of AAV2 than 
lentivirus or adenovirus. Stability of transgene expression following AAV2 injection into the rat 
knee joint supports a potential role for AAV2 gene therapy in treatment strategies for 
inflammatory or degenerative arthritis by facilitating the synthesis of therapeutic factors within 
the joint space. 
Consistent with previous reports of AAV injection into the knee joint of various animals, 
both luciferase and GFP transgene expressions were mostly localized to soft tissues 
(44, 46, 95, 97, 99). GFP imaging with the stereomicroscope provided a more precise 
localization than the bioluminescence imaging system and indicated that few sparse areas of 
GFP-positive cells could be found in articular cartilage. A recent study employing self-
complementary AAV2 injected into the intra-articular joint of guinea pigs also demonstrated 
transgene expression by articular chondrocytes (97). Previous studies using AAV have shown 
higher levels of transgene expression in diseased cartilage compared to normal cartilage (44, 46). 
Seeing that intact and undamaged articular cartilage is unlikely to require treatment, future 
studies will test AAV in rat models of articular cartilage damage, as it will more closely mimic 
the osteoarthritic environment. Abundant transgene expression in soft tissues suggests that cells 
within these tissues, such as those within the infrapatellar fat pad, can uptake the AAV2 and lead 
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to transgene expression. Given the low turnover rate of these cells, intra-articular delivery of 
AAV2 targeted to soft tissues is of value for anti-inflammatory treatment strategies for arthritis 
conditions. For articular cartilage repair, it may be necessary to target more specifically the 
chondrocytes. This may be especially important if delivering genes encoding for bone 
morphogenetic proteins, as their expression in soft tissues could result in ectopic mineralization. 
We and other are exploring strategies for targeted delivery of transgenes to articular 
chondr
pression would not affect 
tissues 
hich is 
larger i
ocytes and chondral defects (42, 107, 108). 
Lack of luciferase signal in the contralateral control knee that did not receive AAV-
CMV-Luc, and lack of signal anywhere else in the animal suggests that intra-articular injection 
limits AAV2 delivery to tissues within the joint and does not travel systemically. This is 
advantageous, as bioactive factors present from viral transgene ex
outside of the joint, and possibly lead to negative side effects. 
The dose of AAV used in this study of 2.5 x 1010 vg/knee joint was chosen based on what 
was previously been shown to be effective in rats (45).  This prior study employed 1010 vg of 
AAV/rat knee joint and reported transgene expression for at least 100 days. The dose chosen for 
our current rat study will need to be increased in order to be effective in a human joint, w
n size and in volume of synovial fluid, resulting in a larger volume of distribution. 
Others have shown that it is feasible to administer AAV to humans through intra-articular 
injection. Human clinical trials for rheumatoid arthritis using a recombinant, single-stranded 
AAV2 vector have performed intra-articular injections at doses ranging from 1011 to 1013 vg/mL 
and 5 mL was injected per joint (88, 109). The authors reported these dosages to be safe and 
feasible, and although some improvement in patient-reported outcomes was observed, the 
transgene expression was not found to be sufficient. It should be noted that humans have serum 
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IgG and neutralizing factors against different types of AAV, representing a limiting factor to 
AAV gene therapy (110). In moving towards direct intra-articular injection of AAV to larger 
joints, it will be important to determine the optimal dose of AAV to deliver and the serotype that 
will fac
 multiple cycles of 
transge
ection of Dox in small animals and oral suspension or pill administration in larger 
animals. 
e the least amount of neutralizing antibodies. 
Studies involving inducible gene therapy for musculoskeletal application have mainly 
focused on genetic engineering of cells ex vivo, followed by their implantation in vivo (75, 111-
113). Direct viral gene delivery is easier to administer, and does not require the additional time 
and cost associated with ex vivo cell-mediated gene delivery. As shown in this study, the 
transgene expression can last for up to a year, which is not the case with implanted cells (42). By 
persisting for a prolonged period of time, there is the possibility to perform
ne expression with a single injection of AAV, as shown in this study. 
We observed increased transgene expression with addition of Dox to the drinking water 
and reduction of transgene expression following its removal at both 14 days and 13 months post-
AAV injection. A similar trend was observed after 8 months. These data demonstrate the 
persistence of the transgene and controllability of its expression. The variability in observed 
transgene expression between the 14 days, 8 months, and 13 months time points could reflect 
type II error due to the small sample size or potentially be related to a difference in Dox intake. 
Adding Dox to the drinking water, while simple and shown in this study to be capable of 
controlling in vivo intra-articular transgene expression, may however lead to some degree of 
variability since free water intake is less well controlled than oral administration as a pill or 
measured suspension. Future studies with inducible gene expression systems may need to use 
direct inj
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Induction of gene expression 13 months post-AAV injection is of clinical relevance when 
a therapeutic protein needs to be re-administered to further promote cartilage repair, or in cases 
where cartilage resumes degrading or inflammation increases and another round of treatment is 
necessary. An inducible AAV2 gene expression system is also of interest for the delivery of 
multiple factors. Different biological molecules could be synthesized at different time points, 
depending on the regulatory transcriptional activator. This would provide a controlled 
environment for cartilage repair, where multiple growth factors are involved. A limitation of the 
inducible AAV2 gene expression system used in this study is the observed leakiness without the 
addition of Dox. This can potentially be addressed in future studies by newer rtTA vectors that 
have been developed to reduce basal activity and that require less Dox to be activated (114).   
2.5 CONCLUSIONS 
In summary, AAV2 delivered by a single intra-articular injection to a normal rat knee joint led to 
persistent and stable transgene expression that was mainly localized to soft tissues of the joint, 
with some expression in chondrocytes. Intra-articular injection of an inducible AAV2 vector 
demonstrated the ability to regulate in vivo transgene expression by oral administration of Dox, a 
compound that is safely used in humans. This regulation was possible immediately after 
delivering the AAV to the knee joint, and 13 months later. Ability to achieve stable yet high 
regulatable long-term intra-articular transgene expression is of potential clinical utility for 
development of new treatment strategies for intra-articular disease processes, such as 
inflammatory and degenerative arthritis.  
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3.0  PERSISTENCE, LOCALIZATION, AND EXTERNAL CONTROL OF 
TRANSGENE EXPRESSION AFTER SINGLE INJECTION OF ADENO-ASSOCIATED 
VIRUS INTO INJURED JOINTS 
3.1 INTRODUCTION 
Traumatic and degenerative injuries to articular cartilage are a leading source of disability. The 
limited healing potential of articular cartilage often leads to development of osteoarthritis (OA). 
OA is a chronic and progressive disease, and patients need to be on medications for a long period 
of time. Common medications for OA include non-selective non-steroidal anti-inflammatory 
drugs (NSAIDs) (115, 116). Chronic and often daily use of these drugs; however, is not without 
significant complications. NSAID therapy results in systemic side effects and is responsible for 
16,500 deaths per year in the US (117). As well, there are no disease modifying treatments for 
osteoarthritis nor a method to completely re-establish cartilage function (79). Cartilage injuries 
or OA affects only a limited number of joints, without major extra-articular or systemic 
symptoms. Hence, delivery of bioactive agents in a localized manner to the injured joints is an 
attractive therapeutic option. It is therefore of critical interest to investigate an effective delivery 
vehicle that targets articular joints. 
A potentially novel and innovative treatment strategy is gene therapy, utilizing viral 
vectors, such as adeno-associated virus (AAV) to deliver therapeutic proteins of interest to 
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affected joints to enhance joint repair or to prevent cartilage degradation. Recombinant AAV is a 
promising delivery vehicle for articular cartilage with the advantages of sustained transgene 
expression, reduced potential for host immune response, and the capacity to transduce both 
dividing and non-dividing cells in vivo and in vitro (108, 118). The viral vector is derived from 
an endemic, non pathogenic parvovirus, and intra-articular injection of AAV has been used in 
clinical trials for delivery of bioactive substances (88, 119). Numerous serotypes of AAV exist, 
each serotype with different preferential targets (44). AAV5 has recently been suggested to have 
better transduction efficiency in rodent arthritic joints; however, AAV2 has the best defined 
safety profile as it is used in clinical trials (48). 
A recently published study from our laboratory has shown both stable and persistent 
reporter transgene expression at one year after a single intra-articular injection of AAV (47). 
Most of the AAV transduction occurred in the intra-articular soft tissues covered with synovial 
lining, with limited articular chondrocyte transduction. This is consistent with other studies, as 
vector penetration through the dense cartilage extracellular matrix is restricted (44, 116). 
However, high level expression of transgene product was possible from the soft tissues. 
Nonetheless, there are potential safety issues concerning long-term or high-dose expression of 
transgenes, in that overexposure could result in undesirable side effects. For this reason, 
controllable vectors have been developed to limit treatment time/dosage to the minimal needed 
to achieve therapeutic efficacy. One novel system is the Tetracycline (Tet)-on promoter, in 
which control is facilitated by using tetracycline molecule as an activator of the promoter, 
stimulating transgene expression only in the presence of the drug (76). Previous studies in our 
laboratory have successfully modulated gene expression utilizing the Tet-on system and 
doxycycline, a tetracycline analog (47). However, as intact/undamaged articular cartilage is 
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unlikely to require treatment, AAV administration strategies in the setting of joint injury will 
provide invaluable information to improve gene therapy strategies for joint restoration. 
This study tests the hypotheses that 1) in vivo AAV transgene expression localizes to 
damaged cartilage when AAV is administered post-injury, 2) AAV injection pre-injury leads to 
the creation of a soft tissue reservoir that persistently expresses transgene products at high levels, 
and 3) in vivo transgene signal can be externally controlled after joint injury using oral 
doxycycline. Two surgically created unilateral joint injuries of high clinical relevance will be 
studied: osteochondral defect (OCD) and anterior cruciate ligament transection (ACLT). 
3.2 METHOD 
3.2.1 AAV preparation 
Double stranded AAV serotype 2 (AAV2) vectors were produced, purified, and vector genome 
(vg) titer determined as previously described (120). AAV2s with constitutively active 
cytomegalovirus (CMV) promoter included AAV2-CMV-Luciferase (Luc) and AAV2-CMV-
reverse-tetracycline-controlled transactivator (rtTA). AAV2 with tetracycline response element 
(TRE) promoter included AAV2-TRE-Luc.  
3.2.2 Explant study 
Femoral cartilage samples from three month old male Sprague Dawley rats (Harlan) were 
harvested, washed in phosphate buffered saline (PBS, Gibco) with 2% penicillin-streptomycin 
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(pen/strep, Gibco) and incubated for 2 – 3 days in 37°C, 5% CO2 in 1:1 ratio Dulbecco’s 
modified Eagle medium (DMEM) and F-12 (DMEM/F-12, Gibco), 10% fetal bovine serum 
(FBS, Gibco), 2% pen/strep, and 1% amphotericin B (Invitrogen). The explants were divided 
into three groups in triplicate: No Injury/No AAV Control, No Injury/AAV-CMV-Luc, Scratch 
injury with AAV-CMV-Luc. The explants from the latter group had the femoral condyles 
scratched with a blade. The explants from the No Injury/AAV-CMV-Luc and Scratch/AAV-
CMV-Luc groups were transduced with AAV-CMV-Luc at a concentration of 80,000 vg/cell in 
serum-free DMEM/F-12. After one hour incubation, the culture media was replaced with fresh 
DMEM/F-12, 10% FBS, 2% pen/strep, and 1% amphotericin B. The culture media was changed 
after two days. The explants were imaged after 96 hours post-AAV transduction, using IVIS® 
Imaging System 200 (Xenogen) by adding 10 μL of 30 mg/mL D-Luciferin Potassium Salt 
(Caliper Life Sciences) per 1 mL of culture media. The images were taken at 1 min exposure.  
3.2.3 Animal studies 
Animal experiments were performed following a University of Pittsburgh Institutional Animal 
Care and Use Committee (IACUC)-approved protocols 0901937 and 1103868. Longitudinal in 
vivo study was performed using forty-eight three month old male Sprague Dawley rats. 
3.2.4 Animal surgeries 
Twenty-four rats underwent unilateral OCD surgeries, while the other twenty-four rats 
underwent ACLT surgeries as previously described (121, 122). Briefly, all the procedures were 
carried out while the animals were anesthesized with inhalation of isoflurane (Phoenix 
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Pharmaceuticals): 2-5% for induction and 0.25-4.0% for maintenance. Rat knee joints were 
exposed via medial parapatellar and medial patellar tendon approaches. The patella was 
dislocated laterally and the knee was flexed. For the OCD surgeries, the midpoint of the femoral 
trochlea was identified and a 1.5 mm carbide tipped drill (Emil Lange/ELA) was used to create 
an OCD approximately 1.0 mm deep. The subchondral bone was penetrated and bleeding bone 
was observed. For the ACLT surgeries, ACL and posterior cruciate ligament (PCL) were 
visualized with the aid of a 3x surgical loupe (Carl Zeiss). Forceps were used to protect the PCL 
and the ACL was severed using a 1.5 mm Cutting Edge Beaver Needle Blade (Becton, 
Dickinson and Company). ACLT was confirmed with an anterior drawer test. Following injury 
creation for both OCD and ACLT, the joint spaces were washed with sterile saline, and both 
capsule and skin were sutured using monofilament 4-0 monocryl (Ethicon). An intramuscular 
injection of 0.2 – 0.5 mg/kg buprenorphine (Hospira) was administered twice per day for two 
days following surgery for analgesia. 
3.2.5 AAV injections 
AAV2-CMV-Luc was used to characterize the persistence and localization of the transgene 
signal while AAV2-TRE-Luc was used to characterize the external controllability of the 
transgene signal using oral doxycycline.  
Two different AAV injection time points were investigated to compare the transgene 
expression levels: post-injury AAV injection and pre-injury AAV injection. For the post-injury 
AAV injection group, the viral vectors were injected bilaterally into both injured and intact joints 
at one week post-injury for OCD rats and three weeks post-injury for ACLT rats. For the pre-
injury AAV injection group, the AAVs were injected bilaterally into the joint. After twenty-eight 
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days, when the transgene expression level has stabilized, the animals underwent unilateral joint 
surgeries, either OCD or ACLT.   
Each knee was given a total of 50 μL of AAVs, containing 2.5 x 1010 vg of either AAV2-
CMV-Luc or AAV2-TRE-Luc and an equal amount of AAV2-CMV-rtTA by single intra-
articular injection. During the injection procedures, animals were anesthesized with gaseous 
isoflurane. Six rats were used for each viral construct per injury model per AAV injection time 
points (Table 3-1). 
Table 3-1: Animal study design 
Two AAV-injection time points were investigated on OCD and ACLT models of joint damage, with N = 6/injury 
type/AAV-injection time point/AAV-construct. 
AAV-injection Timepoint Injury AAV2 construct N
Post-injury 
OCD AAV2-CMV-Luc AAV2-TRE-Luc 
6 
6 
ACLT AAV2-CMV-Luc AAV2-TRE-Luc 
6 
6 
Pre-injury 
OCD AAV2-CMV-Luc AAV2-TRE-Luc 
6 
6 
ACLT AAV2-CMV-Luc AAV2-TRE-Luc 
6 
6 
Total number of rats: 48 
3.2.6 External control of transgene expression 
To induce expression of luciferase in the animals injected with AAV2-TRE-Luc, the rats were 
administered drinking water containing doxycycline (Sigma) at a concentration of 2 mg/mL for 
seven days, followed by its removal. To ensure fresh supply of doxycycline, the water was 
replaced every day and protected from light using amber drinking bottles. Addition of 
doxycycline to the drinking water was performed at 14 days, 3 months, and 6 months post-AAV 
injection. Rats injected with AAV2-CMV-Luc had regular drinking water for the duration of the 
study. 
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3.2.7 Longitudinal in vivo live animal imaging 
At each imaging time point, rats were anesthetized with isoflurane inhalation, followed by a 50 
μL intra-articular injection of 30 mg/mL D-Luciferin Potassium Salt substrate. After 5 minutes, 
rats were placed in and imaged with an IVIS® 200 optical imaging system. Rats injected with 
AAV2-CMV-Luc were imaged every week for the first month, and monthly thereafter, until six 
months post-AAV injection, when the rats were sacrificed. On the day of sacrifice following 
regular imaging as detailed above, rats received a 400 μL intra-peritoneal injection of 30 mg/mL 
D-Luciferin Potassium Salt substrate (Goldbio) to determine if any signal was present outside the 
joint. The joint was then opened to image the intra-articular tissues. Rats injected with AAV2-
TRE-Luc were imaged three times for every oral doxycycline stimulation cycle: pre-doxycycline 
time point prior to addition of doxycycline, 7 days following doxycycline addition, and 7 days 
following doxycycline removal. These rats were sacrificed at six months post-AAV injection as 
well, following the third doxycycline stimulation cycle. All the rats were sacrificed via CO2 
asphyxiation and subsequent thoracotomy.  
3.2.8 Statistical analyses 
All the statistical analyses were performed using Statistical Packages for Social Studies (SPSS) 
17.0 (IBM). Results were judged for significance at p < .05, unless otherwise noted. Explant data 
were observed in triplicate (Fig. 1, n = 3). In vivo animal data were observed using independent 
animals, with N = 6 per group. All the data were tested for assumptions of parametric data: 
Shapiro-Wilk for normality of data distribution and Levine’s for homogeneity of variance. The 
parametric bioluminescence data for the explant study is represented as median and interquartile 
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range boxplots, and analyzed using one-way independent analysis of variance (ANOVA) with 
post hoc Tukey (Fig. 3-1). The longitudinal bioluminescence data for the animal studies 
assessing the persistence and magnitude of the AAV-transgene are represented as line graphs ± 
standard error of mean (SEM) and were analyzed using two-way mixed ANOVA, with main 
independent variables of joint injury status as paired variable and time as repeated variable (Fig. 
3-2 and 3-4). Friedman’s ANOVA test with a Bonferroni correction was used as a post hoc test 
to assess effect of time on each of the injured and intact joints (p < .025 considered significant) 
and Wilcoxon Signed Ranks test with a Bonferroni correction was used as a post hoc test to 
assess the effect of joint injury status at each outcome time points when the interaction effect of 
time between the time and joint injury status was significant (Fig. 3-4B). The bioluminescence 
data assessing controllability of transgene expression were analyzed using one-way repeated 
measured ANOVA (Fig. 3-6). 
3.3 RESULTS 
3.3.1 In vitro AAV transduction of explants 
Transgene expression was observed from femoral cartilage explants transduced with AAV-
CMV-Luc (Fig. 3-1). The bioluminescence signal was greater in No Injury/AAV-CMV-Luc 
group (p = .046) and Scratch/AAV-CMV-Luc group (p = .008) compared to No Injury/No AAV 
Control group. While no difference was observed between the two AAV-CMV-Luc transduced 
groups (p =.313), the mechanical scratch injury model where the condyles were scratched with a 
blade showed brighter bioluminescence at both lateral and medial condyles. 
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Figure 3-1: Explant AAV transduction of rat femoral cartilage 
Rat femoral cartilage explants were either scratched or kept intact (No Injury), after which they were transduced 
with AAV-CMV-Luc. Luciferase signal was detected after 96 h. (A) Representative images of bioluminescence 
signal from the explants. (B) Median and interquartile range of bioluminescence for the different explant groups. n 
= 3. *p < .05 versus No Injury/No AAV Control group. 
3.3.2 AAV transduction in osteochondral defect injury 
AAV transgene expression was persistent in both the OCD and intact joints whether the AAV 
was injected post- or pre-OCD injury (Fig. 3-2). However, the magnitude of the transgene 
expression levels in the OCD joints was different between the two AAV injection time points. 
For the knees with AAV injected post-OCD, there was a significant main effect of the injury 
status on the bioluminescence level (p = .015), where the OCD knees had lower signal than the 
intact knees (Fig. 3-2B). On the other hand, for the knees with AAV injected pre-OCD, the main 
effect of the injury status on the bioluminescence level was non-significant (p = .924, Fig. 3-2D). 
As well, the luciferase expression remained unchanged from the pre-OCD time points. For both 
 40 
the AAV injection time point groups, there was a non-significant main effect of time on the 
bioluminescence level (p = .175 for post-OCD AAV injection and p = .185 for pre-OCD AAV 
injection): the transgene magnitude remained constant throughout the duration of the study for 
each of the joints. The interaction effect between the joint injury status and the time was non-
significant in both cases as well (p = .182 or post-OCD AAV injection and p = .921 for pre-OCD 
AAV injection).  
Figure 3-2: Persistence of AAV transgene in osteochondral defect injury model 
Persistence of in vivo transgene expressions in OCD injured joints with a single intra-articular injection of AAV-
CMV-Luc post-OCD (A and B) or pre-OCD (C and D) were assessed via bioluminescence. (A) Representative 
images of transgene signal from the OCD and intact joints at 7 days, 1 month, and 6 months following AAV-CMV-
Luc injection 1 week after OCD injury. (B) Mean and SEM of bioluminescence observed in the OCD and intact 
joints of all rats in the group over 6 months following AAV-CMV-Luc injection 1 week after OCD injury. (C) 
Representative images of transgene signal from the OCD and intact joints injected with AAV-CMV-Luc 4 weeks 
prior to OCD injury at pre-OCD, 1 month, and 6 months time points. (D) Mean and SEM of bioluminescence 
observed in the OCD and intact joints of all rats in the group over 6 months following OCD injury in joints injected 
with AAV-CMV-Luc 4 weeks prior. N = 6/group.  
 
Upon exposing the intra-articular space, the location of transgene expression was 
different in the OCD injured knees between the two different AAV injection time points (Fig. 3-
3). For both of the AAV injection time points, the intact joints had the diffuse and high 
magnitude signal in the exposed infrapatellar fat pad. However, for the OCD injured joints, the 
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bioluminescence signal was concentrated to the injured cartilage and the associated OCD repair 
tissue in the post-OCD AAV-injected knees (Fig. 3-3A), whereas the signal was more diffusely 
found in intra-articular soft tissues, mainly the fat pad in the pre-OCD AAV-injected knees, with 
no bioluminescence observed in the injured cartilage (Fig. 3-3B). Hence, the pre-OCD AAV-
injected knees had transgene signal location similar to those of the intact joints. 
 
Figure 3-3: Localization of AAV transgene in osteochondral defect injury model 
Intra-articular localization of transgene expressions in OCD injured joints with a single intra-articular injection of 
AAV-CMV-Luc were assessed after exposing the joint on the day of sacrifice using the IVIS optical imaging 
system. (A) Representative intra-articular images of transgene signal from the exposed OCD and intact joints that 
were injected with AAV-CMV-Luc 1 week after OCD injury. (B) Representative intra-articular images of 
transgene signal from the exposed OCD and intact joints that were injected with AAV-CMV-Luc 4 weeks prior to 
OCD injury. 
3.3.3 AAV transduction in anterior cruciate ligament transection injury 
Similarly to the OCD injury model, the transgene expression was persistent in both the ACLT 
and intact joints, and for both post-ACLT and pre-ACLT AAV injections (Fig. 3-4). The 
magnitude of the bioluminescence levels in the ACLT joints was again different between the two 
AAV injection time points. For the joints with AAV injected post-ACLT, there was a significant 
main effect of the injury status (p = .001): the ACLT joints had lower signal than the intact (Fig. 
3-4B). For the knees with AAV injected pre-ACLT, on the other hand, the main effect of the 
injury status was non-significant, with no change in transgene expression from the pre-ACLT 
time points (p = .717, Fig. 3-4D). The main effect of time on the bioluminescence level was 
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significant for the post-ACLT AAV injected group (p = .010) and non-significant for the pre-
ACLT AAV injected group (p = .401). The interaction effect between the joint injury status and 
the time was significant for post-ACLT AAV injection study group (p = .011) and non-
significant for pre-ACLT AAV injection study group (p = .872). Further post hoc testing of the 
post-ACLT AAV injection study group showed that the effect of time on the bioluminescence 
level of the ACLT joints is non-significant for the ACLT injured joints (p = .992). Hence, the 
transgene magnitude remained constant throughout the study period in the ACL injured joints for 
both post-ACLT and pre-ACLT AAV injection groups. 
Figure 3-4: Persistence of AAV transgene in anterior cruciate ligament transection injury model 
Persistence of in vivo transgene expressions in ACL transected joints with a single intra-articular injection of AAV-
CMV-Luc post-ACLT (A and B) or pre-ACLT (C and D) were assessed via bioluminescence. (A) Representative 
images of transgene signal from the ACLT and intact joints at 7 days, 1 month, and 6 months following AAV-CMV-
Luc injection 3 weeks after ACL transection. (B) Mean and SEM of bioluminescence observed in the ACLT and 
intact joints of all rats in the group over 6 months following AAV-CMV-Luc injection 3 weeks after ACL 
transection. (C) Representative images of transgene signal from the ACLT and intact joints injected with AAV-
CMV-Luc 4 weeks prior to ACL transection at pre-ACLT, 1 month, and 6 months time points. (D) Mean and SEM of 
bioluminescence observed in the ACLT and intact joints of all rats in the group over 6 months following ACL 
transection in joints injected with AAV-CMV-Luc 4 weeks prior. N = 6/group.  
 
When the intra-articular space was exposed, the localization of bioluminescence signal 
was different in the ACLT joints between the two different AAV injection time points as well 
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(Fig. 3-5). Consistent with the intact sides of the OCD injury model animals, the intact joints 
showed diffuse signal in the exposed infrapatellar fat pad for both of the AAV injection time 
points. As well, the diffuse bioluminescence signal was found in the infrapatellar fat pad for the 
pre-ACLT AAV-injected ACL transected joints, with no signal found in the cartilage (Fig. 3-5B). 
However, for the post-ACLT AAV-injected ACL transected joints, the bioluminescence signal 
was lower in the intra-articular soft tissues but some region of concentrated signal in the injured 
cartilage (Fig. 3-5A).  
 
Figure 3-5: Localization of AAV transgene in anterior cruciate ligament transection injury model 
Intra-articular localization of transgene expressions in ACL transected joints with a single intra-articular injection 
of AAV-CMV-Luc were assessed after exposing the joint on the day of sacrifice using the IVIS optical imaging 
system. (A) Representative intra-articular images of transgene signal from the exposed ACLT and intact joints that 
were injected with AAV-CMV-Luc 3 week after ACL transection. (B) Representative intra-articular images of 
transgene signal from the exposed ACLT and intact joints that were injected with AAV-CMV-Luc 4 weeks prior 
to ACL transection. 
3.3.4 External control of AAV-transgene expression in injured joints 
Rats that received the inducible AAV2-TRE-Luc showed gene expression upregulation with 
addition of Dox and downregulation following its removal from the drinking water from both the 
OCD and ACLT injured joints (Fig. 3-6). This finding was consistent between the two AAV 
injection time points.  
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Figure 3-6: Controllability of AAV transgene in joint injury models 
Intra-articular transgene expressions in injured joints with a single intra-articular injection of AAV-TRE-Luc post-
injury (A and C) or pre-injury (B and D) were assessed after a cycle of doxycycline addition and removal using the 
IVIS optical imaging system. (A) Representative intra-articular images of transgene signal from the OCD joints that 
were injected with AAV-TRE-Luc 1 week after OCD injury. (B) Representative intra-articular images of transgene 
signal from the OCD joints that were injected with AAV-TRE-Luc 4 weeks prior to OCD injury. (C) Representative 
intra-articular images of transgene signal from the ACLT joints that were injected with AAV-TRE-Luc 3 weeks after 
OCD injury. (D) Representative intra-articular images of transgene signal from the ACLT joints that were injected 
with AAV-TRE-Luc 4 weeks prior to ACL transection. *p < 0.05 compared to Day 0: Pre-Dox.  #p < 0.05 compared 
to Day 7: Dox +. N = 6 rats. 
3.4 DISCUSSION 
Treatment or prevention strategies of pathologic processes within articular joints are severely 
limited. Hence, a successful delivery strategy for adequate levels of therapeutic molecules in a 
localized manner is critically important. Gene therapy strategies, therefore, has gained a lot of 
attention for arthritis treatment (44, 116). Numerous vectors are available for in vivo gene 
transfer, such as naked DNA, retrovirus, adenovirus, etc.; however, most are limited in term of 
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safety, efficacy, and duration (123). AAV, on the other hand, is a very promising vector system 
that may provide the best balance between safety and in vivo gene delivery efficiency (116). 
Methods to localize and control in vivo transgene expression are important to enhance the 
therapeutic efficiency and safety of intra-articular AAV gene therapy. This has been achieved in 
intact joints (47). However, to more closely mimic the osteoarthritic environment, AAV 
transduction to injured cartilage and joints has been investigated.  
We initially characterized the efficacy of AAV transduction in explants culture of 
femoral cartilage. With 80,000 vg/cell AAV2-CMV-Luc, significant transduction was observed 
for rat femoral explants. There was no significant difference with transduction efficacy between 
the two AAV-transduced groups; however, the mechanical injury model where the condyles 
were scratched with a blade showed high intensity of luciferin flux at both lateral and medial 
condyles. This is potentially due to the scratch injury creating a more permeable path to articular 
chondrocytes for AAV transduction. Thus, we expected to have more AAV-transduction in 
damaged areas of articular cartilage. 
For the in vivo animal studies, we chose two commonly used joint injury models of high 
clinical relevance: OCD and ACLT. The timing of AAV injection, pre- or post-joint injury, 
permitted us to characterize the effect of injury on AAV transduction and localization of 
transgene expression. For both of the injury models, AAV transduces and is mainly expressed by 
intra-articular soft tissues in the intact sides, as shown in the previous study (47). However, if the 
AAV is injected after joint injury, as would likely be the case in a clinical setting, the transgene 
signal localizes to the vicinity of the injured cartilage and associated repair tissue. As in the case 
for the explants study, the injured cartilage, with more permeable extracellular matrix, would 
have allowed AAV to travel and traduce the chondrocytes/injury activated repair cells. The 
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transgene expression from the soft tissues was limited for both OCD and ACLT injured joints. 
This can also be due to a number of reasons, such as increased volume of synovial fluid in 
injured joints diluting the intra-articular viral concentrations, injury-activated macrophages 
clearing up the virus prior to effective transduction, or the viral gene promoter shut off in 
response to the injury (124). When the AAV is injected before injury, the transgene signal 
magnitude as well as localization was no different from those of the intact joints. All of the 
transgene expression was found in the soft tissues with no detectable signal from the injured 
cartilage or associated repair tissue. This pre-injury AAV injection data makes the theory that 
promoter shuts off in response to injury less likely.  
 The differential transgene location between the two AAV-injection timepoints can be 
used to optimize AAV-mediated cartilage repair strategies. The highly localized gene expression 
following AAV injection post-injury is advantageous for gene therapy strategies that deliver 
anabolic growth factors that would aid in cartilage repair, especially genes that need to 
specifically target chondrocytes to be effective. Such strategies may include RNA interference 
against various cartilage catabolites, such as aggrecanases/ADAMTSs (70), or chondrogenic 
growth factors that have adverse effects on other intra-articular soft tissues, such as transforming 
growth factor (TGF)-β1. TGF-β1 has been shown to increase chondrocyte matrix synthesis when 
its gene vector was injected in the joint; however, its overexpression from the synovium resulted 
in adverse fibrosis (66).   
Diffuse signal, seen when AAV is injected before creation of injury, is also of potential 
value, as it provides a model to study the delivery of protective factors to individuals that may be 
at high risk for cartilage degeneration. Although the virus does not specifically transduce 
chondrocytes, a high level of transgene expression from surrounding soft tissues still allows for 
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preventative therapeutic approaches by using the soft tissue as a drug depot to release protective 
molecules. The high intra-articular concentrations of secreted products, such as a cytokine 
antagonist like interleukin-1 receptor antagonist protein, can protect the cartilage by competing 
with catabolic factors in the joint (74). Moreover, since synoviocytes release numerous pro-
inflammatory molecules in arthritic conditions, a strong tropism of AAV for the synovium can 
be utilized to suppress expression of any of these injurious compounds (125).  
The controllability of gene expression in intact and injured joints is also important since 
gene expression may not be needed for a prolonged period of time to have a beneficial effect, 
and it provides added means of safety. We have shown this controllability in all the injury 
models, whether the AAV was injected post- or pre-injury using oral administration of 
doxycycline in drinking water. Doxycycline is an analog of tetracycline, an anti-microbial agent 
that is safely used in humans (78). In addition, the use of doxycycline as the transgene inducer 
molecule may have added beneficial effect for cartilage protection. Doxycycline inhibits 
collagen degrading enzymes, such as matrix metalloproteinases (MMPs), and has shown 
beneficial effects in both OCD and ACLT injury models by preventing MMP upregulation 
(121, 126).  
The studies investigating AAV transduction in injured joints are limited, and only 
rheumatoid arthritis injury setting has been explored (44, 46, 127). Two groups used a transgenic 
mice model that spontaneously develops arthritis due to tumor necrosis factor (TNF)-α 
overexpression (44, 127). Goater et. al. reported increased AAV transduction efficiency with 
increased degree of the joint disease following an intra-articular injection of AAV, with 
synoviocytes as the primary target. As well, in vitro transduction efficiencies of synoviocytes 
extracted from the transgenic mice increased with the treatment of these cells with damaging 
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agents, such as irradiation and TNF-α. However, their study was done using single stranded 
AAV, where the second strand synthesis is the limiting step in AAV transgene expression. Hence, 
the injurious agents promote DNA synthesis and thus transgene expression as well. The use of 
double stranded or self complementary AAV has been shown to improve AAV transgene 
expression (73). Zhou et al. showed persistent transgene expression for 120 days following 
AAV-Luc injection in the transgenic mice joints; however, they did not compare their 
bioluminescence level to intact joints, preventing a comparison to our study. Another study 
investigated intra-articular AAV transduction in Sprague Dawley rats damaged via a joint 
injection of lipopolysaccharide (LPS) (46). This study showed positive correlations between 
disease severity and AAV transduction and between disease severity and transgene expression. 
Again, however, these injury models mimic inflammatory/rheumatoid arthritis rather than 
osteoarthritis.  
Limitations of the current investigation include that the models of joint injury were 
surgically induced, which is removed from most human idiopathic osteoarthritis cases. Hence, 
the relevance of the results from this study may be more applicable to joint injuries secondary to 
trauma. However, post-traumatic arthritis, with a known date of onset/injury, is more amenable 
for early intervention strategies such as AAV-mediated gene therapy compared to idiopathic OA 
with less definable time of onset (128). Our current focus was mainly for the characterization of 
AAV-transgene expression in the injured joints. The mechanism behind differential gene 
expression localization between the post-injury and pre-injury AAV injection time points 
remains unresolved and needs further elucidation with sham operated animals, as well as various 
other control groups.   
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3.5 CONCLUSIONS 
While AAV transgene expression was localized to the soft tissues of the uninjured joint and 
injured joints when AAV was injected pre-injury, AAV was able to transduce articular 
chondrocytes within the cartilage matrix when injected following injuries. The explant data 
showing AAV-transduction of articular chondrocytes in damaged cartilage suggests that cartilage 
matrix injury may have facilitated entry of more AAV into the cartilage. The in vivo data 
supports use of AAV for persistent, regulated, and safe intra-articular release of bioactive factors 
from injured joint tissues for cartilage repair/protection. Differential transgene expression 
localizations can be used to optimize AAV-mediated cartilage repair strategies: post-injury AAV 
injection approaches would directly target articular chondrocytes in diseased and injured 
cartilage and pre-injury AAV injection would allow intra-articular delivery of secreted anti-
inflammatory factors for sustained release from soft tissues to protect the joint. This information 
can aid in the design of transgene product that could be used for joint strategies. Overall, these 
data support further study of the in vivo therapeutic potential of AAV for safe and localized 
delivery of bioactive substances to injured joints. This can aid in cartilage repair, which may 
delay or prevent the onset of debilitating osteoarthritis. 
 
 
 
 
 
 
 
 50 
4.0  EFFECTS OF DOXYCYCLINE ON MESENCHYMAL STEM CELL 
CHONDROGENESIS AND CARTILAGE REPAIR 
4.1 INTRODUCTION 
Annually, nearly one million people in the United States are affected by articular cartilage 
injuries. These injuries result in significant disability and have a substantial disease and financial 
burden for the healthcare system and the economy. Articular cartilage has limited capability to 
regenerate or repair following injury, and therefore presents a great therapeutic challenge 
(129, 130). Furthermore, focal cartilage injuries are known to accelerate the degeneration of 
surrounding cartilage, hastening onset of osteoarthritis. Microfracture (bone marrow stimulation) 
is the simplest and most commonly used surgical procedure for many focal cartilage injuries. 
This technique involves the recruitment of bone marrow derived mesenchymal stem cells 
(MSCs) to the defect area in an attempt to stimulate chondrogenesis. However, the repair does 
not restore pristine hyaline cartilage containing type II collagen, but instead results in formation 
of a mechanically inferior fibrocartilage scar primarily composed of type I collagen (129, 130). 
Therefore, new and innovative clinical strategies are needed to improve the type and quality of 
repair tissue in order to prevent the development of osteoarthritis.    
Doxycycline is a widely available and inexpensive anti-microbial agent that is safely used 
in humans (78). In addition, doxycycline is a commonly used inducer molecule for the 
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tetracycline-inducible gene regulation system for controlled gene therapy applications in the 
articular joint as well as other organ systems across multiple animal models (47, 131).  Besides 
these anti-microbial and gene-inducing functions, doxycycline may also have intrinsic benefits to 
cartilage. It has been well established that the tetracycline class of medications have the ability to 
inhibit matrix metalloproteinases (MMPs), specifically MMP-1 (collagenase-1), MMP-3 
(stromelysin), and MMP-13 (collagenase-3), independent of their anti-microbial activity (132-
137). Doxycycline is the tetracycline analog that is most studied for MMP-inhibition, and it has 
been shown to exert a beneficial effect against extracellular matrix (ECM) degradation in 
arthritic diseases, as MMPs are shown to be upregulated in arthritis and following cartilage 
injury (133, 136-139). Down-regulation of MMPs increases the amount of collagens produced 
and retained in the ECM (136). However, despite the existing studies suggesting high potential 
for doxycycline to exert a protective effect against cartilage degeneration, there are limited 
studies evaluating the effects of doxycycline on the repair tissue formed by MSCs following 
bone marrow stimulation.   
This study tests the hypothesis that doxycycline reduces MMP expression, enhances 
human mesenchymal stem cell (hMSC) chondrogenesis and improves in vivo cartilage repair. 
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4.2 METHOD 
4.2.1 In vitro studies 
4.2.1.1 hMSC chondrogenic differentiation 
Human MSCs were obtained, processed, and maintained as previously described (57). MSCs at 
passage 3 underwent chondrogenesis as previously described pellet culture assay (57). Briefly, 
2.5 x 105 hMSCs were pelleted by centrifugation in 15 mL conical polypropylene tubes at 500 x 
g for 15 min. The pellets were cultured in 0.5 mL of pre-defined chondrogenic medium 
containing high-glucose Dulbecco’s modified Eagle medium (DMEM, Gibco), with 1% 
penicillin-streptomycin (Gibco), 10-7 M dexamethasone (Sigma-Aldrich), 50 μg/mL L-ascorbic 
acid-2-phosphate (Sigma-Aldrich), 40 μg/mL proline (MP biomedicals), and 1% BD™ ITS+ 
Premix (Becton-Dickinson), 10 ng/mL transforming growth factor-beta1 (TGF-β1, R&D 
Systems). The chondrogenic medium was supplemented with 0, 1, or 2 μg/mL of doxycycline. 
The pellets were incubated at 37°C in 5% CO2 for 3, 7, 14, or 21 days, and the media was 
refreshed every 2 – 3 days. 
4.2.1.2 Chondrogenic hMSC pellet assessments 
4.2.1.2.1  Pellet area and histological evaluation 
After 14- and 21-days of chondrogenic culture, three hMSC pellets per group were collected and 
assessed macroscopically using stereomicroscopy (MVX-10 MacroView Systems, Olympus) 
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equipped with a DP71 camera (Olympus). The pellet area was measured using DP2-BSW 
software (Olympus). The pellets were subsequently fixed in 10% buffered formalin and 
embedded in paraffin for histological analyses. Five-μm cross-sections were stained with 
Safranin O-Fast green for sulfated glycosaminoglycan (GAG) and alizarin red for calcium, and 
immunostained for MMP-13 according to standard protocols. Briefly for MMP-13 
immunohistochemistry (IHC), sections were de-paraffined and rehydrated via conventional 
methods. Antigen retrieval was performed by heating and cooling the slides in 10-mM sodium 
citrate (pH 6.0) with 0.05% Tween-20 buffer (Sigma-Aldrich) for 20 minutes each at 85°C and 
room temperature. The sections were then digested in 1 mg/mL hyaluronidase in 0.1 M sodium 
acetate buffer (both from Sigma-Aldrich) for 30 minutes in 37°C. The hyaluronidase-digested 
sections were blocked with 10% goat serum (Vector Laboratories) and 1% bovine serum 
albumin (BSA, Fisher Scientific) for 1 hour. The sections were incubated with a rabbit 
polyclonal antibody against MMP-13 (Abcam) at 1:100 dilution in 1% BSA solution overnight at 
4°C. Endogenous peroxidase was blocked using 0.3% hydrogen peroxide (Sigma) in tris-
buffered saline (TBS, Calbiochem) for 15 minutes at room temperature. The slides were then 
treated with secondary goat polyclonal anti-rabbit antibody (Abcam) in 1% BSA solution in 
1:100 dilution for an hour, then developed using ImmPACT™ AEC Peroxidase Substrate 
(Vector Laboratories), according to the manufacturer’s instructions. The slides were 
counterstained with hematoxylin (Vector Laboratories). Images of all the stained sections were 
captured using TE-2000U Eclipse microscope (Nikon) equipped with a DP71 camera. The 
MMP-13 IHC images in Fig. 4 had the contrast increased by the same value in Adobe Photoshop 
CS4 to improve MMP-13-positive and -negative cell contrast for print. 
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4.2.1.2.2  Biochemical analyses 
After 3, 7, 14, and 21 days of chondrogenic culture, three hMSC pellets per group were washed 
with phosphate buffered saline (PBS, Gibco) and each dry pellet was frozen at -80°C until 
biochemical analyses. Each frozen pellet was incubated overnight in 0.25 mL papain buffer (50 
mM sodium phosphate buffer (Sigma-Aldrich), 5 mM ethylenediaminetetraacetic acid (EDTA, 
Gibco), 5 mM cysteine HCl (Sigma-Aldrich), and 0.5 mg/mL papain (Sigma-Aldrich)) in 60°C 
shaking water bath (200 RPM). The papain-digested pellets were vortexed. GAG content was 
quantified using the standard dimethylmethylene blue (DMMB) assay using VersaMax UV-Vis 
spectrophotometer (Molecular Devices) (57), and DNA content was quantified using Quanti-
iT™ PicoGreen® dsDNA Reagent and Kits (Molecular Probes) per manufacturer’s protocol 
using a VICTOR™ X3 Multilabel Plate Reader (Perkin Elmer). The GAG/DNA ratios were 
calculated from the results of these two assays. 
4.2.1.2.3  Gene expression analyses 
Three hMSC pellets per group at 3, 7, 14, and 21 days of chondrogenic culture were washed with 
PBS and frozen at -80°C until gene expression analyses. Total RNA was extracted from each 
frozen pellets using TRIzol (Invitrogen). Briefly, pellets in 0.3 mL TRIzol were grinded using 
microtube pestles (USA Scientific), and the ground pellet samples were homogenized using 
QIAshredder columns (Qiagen). The lysate was transferred to a new 1.5 mL tube and incubated 
at room temperature for 5 minutes, after which the contents were centrifuged at 12,000 x g for 10 
min at 4°C. RNease Mini Kit (Qiagen) was used for the rest of the RNA isolating process per 
manufacturer’s protocol. The pre-designed human aggrecan, collagen-II, collagen-I, collagen-X, 
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mmp-13 and 18S TaqMan primers were purchased from Applied Biosystems. Custom human 
sox-9 primers and probe (108) and human transforming growth factor-beta receptor II primers 
(forward: TCCACGTGTGCCAACAACATCAAC; reverse: 
TGCCACTGTCTCAAACTGCTCTGA) and FAM-labeled probe 
(ACAACACAGAGCTGCTGCCCATTG) were purchased from Integrated DNA Technologies. 
qRT-PCR reactions were done in duplicate in 384 well plates in a total volume of 10 μL as 
previously described (108) using 2x real-time TaqMan PCR Master Mix with an ABI PRISM 
7700 Sequence Detection System (Applied Biosystems). Relative expression levels normalized 
to 18S were calculated using the 2-ΔCt method. 
4.2.2 In vivo studies 
4.2.2.1 Animal surgeries 
All longitudinal animal experiments were performed following a University of Pittsburgh 
Institutional Animal Care and Use Committee (IACUC) approved protocol (Protocol No. 
1103868) using the previously established OCD model (42, 140). Briefly, OCD creation on 
twenty-four three-month old Sprague Dawley rats (Harlan) was performed under general gaseous 
anesthesia (Isoflurane, Phoenix Pharmaceuticals). The knees were shaved and swabbed with 
betadine and ethanol. A medial parapatellar approach was utilized to access the stifle joint. The 
patella was dislocated laterally and the knee was flexed to greater than 90-degrees to deliver the 
femoral trochlea into operative view. The trochlear groove was identified and the midpoint of the 
trochlea, which was the midpoint in the superior to inferior dimension at the center of the 
trochlear groove, was marked. A 1.5-mm drill was used to create the OCD, at a depth of 1.0-mm. 
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The subchondral bone was penetrated until bleeding bone was identified. Sterile saline was used 
to gently irrigate the area to remove any osteochondral fragments, and the incision was closed in 
layers. The animals were placed in standard cages with full access to food and water post-
operatively. Subcutaneous buprenorphine (Reckitt Benckiser Healthcare) at 0.5 mg/kg dosage  
 was injected twice daily for the first two-days following surgery as post-operative analgesia. 
Most of the study animals survived the OCD surgeries, except for one death associated with 
anesthesia complication. Hence, the number of animals per group in the in vivo study were N = 
11 for No Doxycycline Control group and N = 12 for 12 Week Doxycycline group. The animals 
received either regular drinking water or 2 mg/mL doxycycline (Sigma-Aldrich) in the drinking 
water. Doxycycline water was replaced daily to ensure fresh supply of doxycycline. 
  
Table 4-1: ICRS Cartilage Repair Scoring System 
 Criteria Points Scores
Degree of defect repair  
In level with surrounding cartilage 4 
75% repair of defect depth 3 
50% repair of defect depth 2 
25% repair of defect depth 1 
0% repair of defect depth 0 
Integration to border zone  
Complete integration with surrounding cartilage 4 
Demarcating border < 1mm 3 
¾ of repair tissue integrated, ¼ with a notable border > 1 mm 2 
½ of repair tissue integrated with surrounding cartilage, ½ with a notable 
border > 1 mm 1 
From no contact to ¼ of repair tissue integrated with surrounding cartilage 0 
Macroscopic appearance  
Intact smooth surface 4 
Fibrillated surface 3 
Small, scattered fissures or cracks 2 
Several, small, or few but large fissures 1 
Total degeneration of defect area 0 
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4.2.2.2 Repair tissue assessments 
Following sacrifice by carbon dioxide asphyxiation at 12 weeks post-OCD surgery, the joints 
were dissected and the repair tissue was examined grossly using three-dimensional (3D) optical 
coherence tomography (OCT) scanning system with a 1,310 nm center wavelength (Bioptigen) 
as previously described (141). The specimens were also analyzed with the aforementioned 
stereomicroscopy and camera, with/without india ink staining for gross grading using the ICRS-
Cartilage Repair Assessment system (Table 4-1) (142). The harvested femurs were then fixed, 
decalcified, embedded in paraffin, and subsequently sectioned. The sections were stained using 
traditional hematoxylin and eosin (H&E) staining, as well as immunostained using rabbit 
polyclonal antibody against MMP-13. The stained sections were imaged using DP71 camera and 
Eclipse TE2000-U microscope, and evaluated using modified Holland histological scoring 
system (Table 4-2) (42). Three independent blinded individuals graded both the gross and 
sectioned histologic specimens, and the scores were averaged for statistical analyses. For the 
estimate percentages of MMP-13-positive cells, the sections from four selected knees from each 
treatment groups were imaged at high-power fields (magnification, x 20). Positive and negative 
cells were counted using ImageJ software (NIH), and percentages were calculated by dividing 
the numbers of MMP-13-stained cells by the sum of the numbers of MMP-13-stained and 
unstained cells. On average, 304 cells were counted per OCD repair tissue. The MMP-13 IHC 
images in Fig. 4-6C had the contrast increased by the same value in Adobe Photoshop CS4 to 
improve MMP-13-positive and -negative cell contrast for print and cell counting. 
 
 
 
Table 4-2: Modified Holland Histological Scoring System 
 Criteria  Points Scores 
Overall defect evaluation (throughout the entire defect depth) 
 Percentage filling with neoformed tissue (%)  
100  3 
>50  2 
<50  1 
0  0 
Subchondral bone evaluation  
 Percentage filling with neoformed tissue (%)  
100  3 
>50  2 
<50  1 
0  0 
 Subchondral bone morphology  
Normal trabecular bone  4 
Trabecular, with some compact bone  3 
Compact bone  2 
Compact bone and fibrous tissue  1 
Only fibrous tissue or no tissue  0 
 Extent of neotissue bonding with adjacent bone 
Complete on both edges  3 
Complete on one edge  2 
Partial on both edges  1 
Without continuity on either edge  0 
Cartilage evaluation  
 Morphology of neoformed surface tissue  
Extensively articular cartilage  4 
Mainly hyaline cartilage  3 
Fibrocartilage (spherical morphology observed with 
>75% of cells)  2 
Only fibrous tissue (spherical morphology observed 
with <75% of cells)  1 
No tissue  0 
 Thickness of neoformed cartilage  
Similar to the surrounding cartilage  3 
Greater than surrounding cartilage  2 
Less than the surrounding cartilage  1 
No cartilage  0 
 Joint surface regularity  
Smooth, intact surface  3 
Surface fissures (<25% neosurface thickness)  2 
Deep fissures (25-99% neosurface thickness)  1 
Complete disruption of the neosurface  0 
4.2.3 Statistical analyses 
All the statistical analyses were conducted using Statistical Package for Social Studies (SPSS) 
17.0 for Windows (IBM). Assumptions of parametric data were tested for all data: normality of 
data distribution with Shapiro–Wilk and homogeneity of variance with Levene’s tests. P-values 
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of less than 0.05 were considered significant, unless otherwise noted. In vitro studies were 
performed in triplicate (n = 3), and data are reported as line graphs with mean ± standard error of 
mean (SEM) (Figs. 4-1 – 3). In vivo studies were conducted and data observed using independent 
animals, with N = 11 for No Doxycycline Control group and N = 12 for 12 Week Doxycycline 
group, and data are reported as bar graphs with mean ± SEM for parametric data (Fig. 4-5) and 
as a boxplot with median and interquartile range for non-parametric data (Fig. 4-6B). For 
comparison among three groups and multiple time points for the in vitro data, two-way 
independent analysis of variance (ANOVA) was used with doxycycline concentration and time 
points as main independent variables. For variables that were considered significant, post-hoc 
Tukey was used to further evaluate the data. For comparisons between two groups for the in vivo 
data, unpaired Student’s t-test was used for parametric data (Figs. 4-5C) and Mann-Whitney U 
test was used for non-parametric data (Fig. 4-6B). 
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4.3 RESULTS 
 
Figure 4-1: Macroscopic appearance of hMSC pellets and pellet area analysis 
(A) Macroscopic images of hMSC pellets cultured in chondrogenic media with 0, 1, or 2 μg/mL doxycycline 
(Dox) for 14 and 21 days. (B) Pellet area measured from the macroscopic images of hMSC pellets cultured in 
chondrogenic media with 0, 1, or 2 μg/mL Dox for 14 and 21 days. Pellet area increased from 14 to 21 days in 
chondrogenic culture period (p = 0.002). As well, the pellet area was significantly affected by the doxycycline 
concentration in the chondrogenic media (p = 0.002): 0 μg/mL Dox pellets were smaller than the 1 μg/mL (p = 
0.014) and 2 μg/mL (p = 0.002) Dox pellets. There was no difference in sizes between the 1 and 2 μg/mL Dox 
pellets (p = 0.535). n = 3/group. 
4.3.1 Gross evaluation of hMSC chondrogenic pellets (Fig. 4-1) 
Gross images of the hMSC chondrogenic pellets were taken at 14 and 21 days of culture in 
chondrogenic media supplemented with 0, 1, or 2 μg/mL of doxycycline (Fig. 4-1A). When the 
pellet areas were measured, an increasing trend in pellet areas from 14 to 21 days in 
chondrogenic culture was seen (Fig. 4-1B). The areas of hMSC chondrogenic pellets were 
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significantly affected by both the concentration of doxycycline (p = 0.002) and the time in 
chondrogenic culture (p = 0.002). The post-hoc Tukey test revealed that the pellet areas were 
significantly larger for those cultured in 1 μg/mL (p = 0.014) and 2 μg/mL (p = 0.002) of 
doxycycline compared to those cultured without any addition of doxycycline. There was no 
significant difference in pellet areas between those cultured in 1 and 2 μg/mL doxycycline. The 
interaction effect between the two main variables, doxycycline concentration and culture time, 
was also non-significant (p = 0.377). 
Figure 4-2: Biochemical quantification of GAG and DNA in hMSC pellets 
(A) Total GAG content per hMSC pellets showed increasing GAG content with longer chondrogenic culture time 
(p < 0.001), with GAG content of the 7 day pellets significantly greater than those of the 3 day pellets (p < 0.001), 
those of 14 day pellets significantly greater than those of the 7 day pellets (p < 0.001), and those of 21 day pellets 
significantly greater than those of the 14 day pellet (p < 0.001). There was no significant effect of doxycycline 
(Dox) concentration on the total GAG content (p = 0.412). (B) Total DNA content per hMSC pellets showed 
significant effect of chondrogenic culture time on the DNA contents (p < 0.001): DNA content of the 3 day pellets 
were significantly lower than those of the 7 (p < 0.001), 14 (p < 0.001), and 21 (p = 0.009) day pellets. There was 
no difference in DNA content among 7, 14, and 21 day pellets. As well, there was no significant effect of 
doxycycline concentration on the DNA content (p = 0.314). (C) Normalized GAG content with respect to the 
DNA content showed that there is significant effect of chondrogenic culture time (p < 0.001); however, the effect 
of doxycycline concentration was not significant (p = 1.000). n = 3/group.
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4.3.2 Biochemical analyses of hMSC chondrogenic pellets (Fig. 4-2) 
Total GAG (Fig. 4-2A) and DNA (Fig. 4-2B) content per pellet samples and their ratio (Fig. 4-
2C) were measured and calculated on 3, 7, 14, and 21 day old chondrogenic pellets to analyze 
the effect of doxycycline on hMSC chondrogenesis and proliferation/viability. For all three 
outcome measures, there was a significant main effect of the time in chondrogenic culture (ps < 
0.001); however, the main effect of doxycycline concentration and the interaction effects were 
non-significant. The post-hoc Tukey tests for total GAG content and GAG/DNA ratio revealed 
significant differences of these outcome variables between all the different time points (ps < 
0.001). On the other hand, the post-hoc Tukey test for total DNA content showed significant 
differences between day 3 and day 7 (p < 0.001), day 14 (p < 0.001), and day 21 (p = 0.009), but 
no significant differences between any other days. 
4.3.3 Gene expression analyses of hMSC chondrogenic pellets (Fig. 4-3) 
Various mRNA levels were measured on 3, 7, 14, and 21 day old chondrogenic pellets to analyze 
the effect of doxycycline on hMSC chondrogenesis. The time in chondrogenic culture had 
significant effect on gene expressions for all the assayed genes: sox-9 (p = 0.001), tgf-βRII (p = 
0.003), aggrecan (p < 0.001), collagen-II (p < 0.001), collagen-I (p = 0.028), collagen-X (p < 
0.001), and mmp-13 (p < 0.001). The main effect of doxycycline concentration as well as 
interaction effects between the two main independent variables were non-significant for sox-9, 
tgf-βRII, aggrecan, collagen-II, collagen-I, and collagen-X mRNA levels. For the mmp-13 gene 
expression, on the other hand, there was a non-significant main effect of doxycycline 
concentration but a significant interaction effect between the time in chondrogenic culture and 
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doxycycline concentration (p = 0.025). This indicates that the doxycycline concentration affected 
mmp-13 mRNA level differently on various chondrogenic culture time points. Specifically, 
mmp-13 levels for all three doxycycline concentrations were similar for day 3, 7, and 14 hMSC 
pellets; however, they were different for day 21 pellets (p = 0.012). The 2 μg/mL doxycycline 
pellets had significantly lower mmp-13 mRNA level compared to 0 μg/mL doxycycline pellets (p 
= 0.010). It was lower compared to 1 μg/mL doxycycline pellets as well, however not to a 
significant extent (p = 0.078). 
Figure 4-3: Gene expression analyses of hMSC pellets 
Messenger RNA levels of chondrogenic inducers sox-9 and tgf-βRII, chondrogenic genes aggrecan and col-II, 
fibrocartilage marker col-I, and hypertrophic chondrocyte marker col-X, and catabolic gene mmp-13. There was an 
increasing trend in sox-9, tgf-βRII, aggrecan, col-II, and col-X levels (ps < 0.01), and a decreasing trend in col-I level 
(p = 0.028) over chondrogenic culture time. There was no significant effect of doxycycline concentration on these 
gene expressions (ps > 0.05). For mmp-13 level, there was an upward trend until day 14, with mRNA level in the 14 
day pellets significantly higher than those of the 3 (p < 0.001) and 7 (p < 0.001) days. However, on day 21, there was 
a reduction in the mRNA level from day 14 (p < 0.001). The mmp-13 mRNA levels on day 21 pellets were also 
significantly different among different doxycycline concentrations: 2 μg/mL doxycycline (Dox) pellets had 
significantly lower mmp-13 levels compared to 0 μg/mL Dox pellets (p = 0.01). n = 3/group. 
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4.3.4 Histological analyses of hMSC chondrogenic pellets (Fig. 4-4) 
Safranin O-fast green staining of sulfated GAGs showed increased amount of staining for 21 day 
versus 14 day hMSC pellets (Fig. 4-4A). However, no differences in staining intensities were 
appreciable among the three different doxycycline concentrations. These results confirm the 
biochemical analysis of total GAG content (Fig. 4-2A). The MMP-13 IHC showed more MMP-
13-positive cells for the 0 and 1 μg/mL doxycycline pellets at Day 21 (Fig. 4-4B), confirming the 
mRNA results (Fig. 4-3). As upregulation of MMP-13 in MSC chondrogenesis has also been 
linked to terminal differentiation of hypertrophic chondrocytes (143-145), alizarin red staining 
was performed. However, there were no positively stained pellets at either doxycycline 
concentration at both 14 and 21 days chondrogenic culture time points (Fig. 4-4C). 
Figure 4-4: Histological analyses of hMSC pellets 
Representative images of (A) safranin-O fast green, (B) MMP-13 immunohistochemistry, and (C) alizarin red 
staining of hMSC pellets at 20x (larger box) and at 4x (smaller inset). There was no difference in staining intensities 
for Safranin-O fast green and alizarin red staining among different doxycycline concentration groups at each time 
point. However, more MMP-13-positive cells were found in the periphery of the hMSC pellets cultured in 0 and 1 
μg/mL doxycycline compared to those cultured in 2 μg/mL doxycycline.
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Figure 4-5: Gross assessment of osteochondral defect repair tissues 
Representative images of repair tissues from No Doxycycline Control and 12 Week Doxycycline groups evaluated 
using (A) 3D OCR and (B) stereomicroscopy. (C) Gross grading of OCD repair tissues using ICRS Cartilage 
Repair Assessment grades showed better repair tissue for the 12 Week Doxycycline group. N = 11 – 12/group.
4.3.5 Evaluation of osteochondral defect repair tissue (Fig. 4-5) 
The OCD repair tissues from the 12 Week Doxycycline group showed more complete repair 
tissue within the femoral trochlear groove by gross inspection and in situ Optical Coherence 
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Tomography (Fig. 4-5A). The animals that received doxycycline for 12 weeks post-op had 
higher mean total ICRS Cartilage Repair Scores reflecting better quality repairs than the No 
Doxycycline Control group (Fig. 4-5C, p = .017). Qualitative evaluation using the modified 
Holland Histological scoring of the H&E stained OCD repair tissue showed similar scores 
between the two groups  (p = .116). 
Figure 4-6: MMP-13 of osteochondral defect repair tissues 
 (A) Representative 4x (larger box) and 20x (smaller inset) images of MMP-13 immunohistochemical staining of 
repair tissues from No Doxycycline Control and 12 Week Doxycycline groups (B) Median and interquartile range 
of percentage of MMP-13-positive cells in different treatment groups. More MMP-13-positive cells were found in 
the newly formed repair tissues of No Doxycycline Control group compared to those of 12 Week Doxycycline 
group (p = 0.029). N = 4/group.  
4.3.6 MMP-13 of OCD repair tissue (Fig. 4-6) 
The repair tissues from No Doxycycline Control group showed more MMP-13-positive cells 
compared to those of 12 Week Doxycycline group (Fig 4-6A): No Doxycycline Control group 
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had 80% MMP-13-positive cells, whereas 12 Week Doxycycline group had 44% MMP-13-
positive cells (Fig 4-6B, p = .029). This in vivo OCD repair tissue MMP-13 content result 
correlates to the in vitro hMSC pellet data (Fig. 4-4B). 
4.4 DISCUSSION 
Osteoarthritis currently affects 27 million adults and costs 3% of the GDP in the US (5, 146). 
The prevalence of osteoarthritis will continue to rise, especially with the aging population and 
the growing epidemic of obesity. By 2030 it is projected to affect 67 million, with 3.5 million 
total knee arthroplasties performed annually (5, 146). Therefore there is significant clinical as 
well as research interest in finding novel ways to improve the quality of cartilage repair. 
Articular cartilage repair with MSCs is widely studied; however, results are often suboptimal to 
prevent osteoarthritis.  
Oral administration of doxycycline has been postulated to have beneficial effects on 
articular cartilage by inhibiting important classes of MMPs (132, 147). Doxycycline 
administration in vivo has resulted in significant decreases in MMP levels in small animal 
models, as well as in human osteoarthritic patients (148, 149). When doxycycline was 
administrated prophylactically in several animal models, the decreased activities of MMPs were 
correlated to reduced proteoglycan loss from cartilage extracellular matrix, as well as reduced 
degenerative changes in the weight-bearing areas of cartilage (126, 150). In a randomized, 
double-blinded, placebo-controlled study that evaluated the effects of doxycycline on the 
progression of joint space narrowing in mildly arthritic knees, the doxycycline treatment group 
had a decreased rate of narrowing by 40% at 16-months and 33% at 30-months as compared to 
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placebo (p = .017) (133). On the other hand, however, a number of other studies show lack of 
any effect on joint disease and/or MMP activities with doxycycline treatment. In a prospective 
clinical study involving dogs with stifle joint instability, there was no significant difference in 
MMP activity levels in synovial fluid for doxycycline versus no doxycycline treatment groups 
(144). In another study involving guinea pigs, oral doxycycline treatment for 4 – 8 months lead 
to no significant OA changes compared to controls (151). Hence there are numerous studies on 
the effect of doxycycline on cartilage degeneration, with conflicting results. Nonetheless, 
doxycycline effect on cartilage repair with MSCs as well as MSC chondrogenesis is largely 
unknown. 
Our laboratory has also previously utilized doxycycline as a control molecule for external 
control of adeno-associated virus (AAV)-mediated transgene expression, as potential strategy to 
deliver therapeutic proteins of interest to affected joints to enhance MSC chondrogenesis, 
thereby improving cartilage repair (47). Intra-articular injection of AAV has been used in clinical 
trials for delivery of bioactive substances (88), and our previous study has shown both stable and 
persistent reporter transgene expression at one year after a single intra-articular injection of AAV 
(47). Nonetheless, there are potential safety issues concerning long-term or high-dose expression 
of transgenes, such as overexposure resulting in undesirable side effects. For this reason, 
controllable vectors have been developed to limit treatment time/dosage to the minimal needed 
to achieve therapeutic efficacy. One novel system is the Tet-on promoter, in which control is 
facilitated by using tetracycline-class drugs as activators of the tetracycline response element 
(TRE)-promoter, stimulating transgene expression only in the presence of the drug. Previous 
studies in our laboratory have successfully modulated gene expression utilizing the Tet-on 
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system with oral administration of 2 mg/mL doxycycline (47), providing an added measure of 
safety, as well as the ability to alter the timing and duration of exposure to bioactive factors.  
Our comprehensive in vitro study shows that doxycycline reduced the MMP-13 gene as 
well as protein expressions at day 21 of chondrogenic culture period. This is consistent with 
MMP-13 suppressing activity of doxycycline found in other tissue types, such as chondrocytes 
and synoviocytes (134, 136). We also observed larger hMSC pellets in the doxycycline group. 
The larger hMSC pellet sizes may be in part due to improved matrix synthesis through inhibition 
of MMP-13 production. As the predominant function of MMP-13 in cartilaginous ECM is 
collagen-II breakdown (134, 144), this MMP-13 inhibition would ultimately lead to reduction of 
excessive collagen-II degradation or enhancement of collagen-II accumulation. MMP-13 is also 
a marker of terminal differentiation of MSCs into hypertrophic chondrocytes (143-145). 
However, lack of differences in col-X gene expression level and lack of alizarin-red positive 
staining among hMSC pellets cultured in various doxycycline concentrations suggest that 
doxycycline is not principally involved in inhibition of MSC hypertrophy.  
Our in vivo data additionally suggests that oral administration of doxycycline potentially 
improves the repair. As well, MMP-13 expression in OCD repair tissue samples was 
significantly greater in No Doxycycline Control than in 12 Week Doxycycline groups. This can 
potentially explain the higher quality repairs reflected in the ICRS scores in the doxycycline 
treated rats. Furthermore, this in vivo finding is correlated to the in vitro findings of MMP-13 
levels in control versus doxycycline-treated MSC pellets.  
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4.5 CONCLUSIONS 
In summary, we showed in both in vitro and in vivo study that doxycycline inhibited MMP-13 
and potentially improved in chondrogenesis and cartilage repair. There was significant inhibition 
of MMP-13 on both mRNA and protein levels in hMSC cultured with 2-µg/mL doxycycline, 
which would lead to reduction of collagen-II degradation and hence larger pellet size potentially 
due to enhanced collagen-II retention. The doxycycline-mediated inhibition of MMP-13 
expression in MSCs is consistent with other studies using doxycycline on other joint cell and 
tissue types. Oral administration of doxycycline visibly improved osteochondral defect repair 
tissues in vivo. The doxycycline-mediated downregulation of MMP-13 expression was observed 
in OCD repair tissues. These findings suggest that doxycycline can be used as an agent for 
external control of transgene expression in cartilage repair studies incorporating AAV-mediated 
gene therapy strategies without interfering with the repair process. Doxycycline inhibition of 
MMP-13 may even potentially improve in vivo cartilage repair. As such, continued evaluation of 
the potential benefits of doxycycline to articular cartilage may lead to novel treatment strategies 
improve cartilage repair and delay development of osteoarthritis. 
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5.0  RELEASE OF BIOACTIVE ADENO-ASSOCIATED VIRUS FROM FIBRIN 
SCAFFOLDS: EFFECTS OF FIBRIN GLUE CONCENTRATIONS 
5.1 INTRODUCTION 
Articular cartilage has a limited self-regeneration capacity and recombinant adeno-associated 
virus (AAV) is a promising vehicle for articular cartilage and the surrounding soft tissues to 
deliver bioactive factors to promote joint restoration. There are three approaches for AAV 
administration to articular cartilage: direct, indirect, and hybrid. The direct method involves an 
intra-articular injection of viral vectors into the articular joint space for their transduction of local 
cells. Although long-term persistence and transgene expression has been observed with direct 
injection of AAV (47), most of the transduction occurs in soft tissues and it is difficult to localize 
the transduction to specific cell types. Further, rapid dispersion of viral particles from the joint 
space would prevent effective transduction of repair cells that are recruited to the defect site over 
time. Thus, the in vivo transduction efficiency remains low and non-specific transduction of 
adjacent tissues and their transgene expression at undesired sites is usually observed (53). The 
indirect approach involves implantation of cells that were genetically modified ex vivo, and faces 
high clinical translational barriers. The hybrid approach, involving implantation of bioscaffold 
embedded with genetic material in the site of defect, leads to direct and localized transduction of 
host cells in situ and sustained expression of the transgene. Further, scaffolds can act as support 
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for injury-activated repair or progenitor cells, such as bone marrow-derived mesenchymal stem 
cells (BM-MSCs), to migrate, attach, and differentiate at the defect site. Thus, the hybrid method 
offers the advantages of site-specific localization, direct transduction of host repair cells, and 
sustained transgene expression, while limiting the disadvantages of indiscriminate transduction 
and requirement of ex vivo manipulations. 
Our group has previously shown that AAV2-transforming growth factor-β1 (AAV2-
TGF-β1) transduced human MSCs (hMSCs) implanted into a 1.5-mm diameter osteochondral 
defect significantly improved cartilage regeneration over 12 weeks in vivo (42). These results 
demonstrated that AAV2 is a suitable vector for gene delivery to improve the cartilage repair 
potential of the MSCs. However, although the ex vivo gene transfer is effective, the regulatory 
barriers for using genetically modified cultured human cells for therapeutic purposes clinically 
are extremely high. In addition, extraction and expansion of MSCs prolong the time before 
treatment can be applied and are very expensive. Therefore, we have explored the use of 
biodegradable scaffolds for release and delivery of bioactive substances to host MSCs within 
cartilage wound (140, 152-154). 
Fibrin glue (FG) is used in a variety of clinical applications and in the laboratory for 
localized and sustained release of factors potentially important for tissue engineering. It has been 
shown that diluted FG produces a more open fibrin network compared to undiluted FG scaffolds 
(155), and that FG can act as an efficient scaffold for gene delivery (156-158). However, the 
effect of different fibrinogen concentrations on FG scaffold delivery of bioactive AAVs has not 
been established.  
In the current study, we investigated the effect of different fibrinogen dilutions during the 
preparation of FG scaffold on the delivery of AAV2 and their early effects on human BM-MSC 
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(hBM-MSC) chondrogenesis in vitro. The aim of this study was to test the hypotheses that 
diluted FG scaffolds will release more viral particles, resulting in higher transduction efficiency, 
and increase the chondrogenic potential of transduced hBM-MSCs. 
5.2 METHODS 
5.2.1 Preparation of FG 
Chemicals were purchased from Sigma-Aldrich unless otherwise stated. Twenty-four well plates 
and 24-well plate inserts were purchased from BD biosciences. Commercially available Tisseel® 
human fibrin sealant (Baxter) was used to construct FG hydrogels. Fibrinogen (100% of the 
original material concentration, lyophilized human fibrinogen reconstituted in aprotinin 
fibrinolysis inhibitor) was prepared by serial dilution with phosphate buffered saline (PBS, 
Gibco) into four different concentrations: 25%, 50%, 75%, and 100% fibrinogen. Different 
dilutions of fibrinogen were subsequently mixed with an equal volume (1:1 volume ratio) of 
thrombin solution provided in the Tisseel kit (human thrombin 400 – 625 IU/mL and calcium 
chloride 36 – 44 μmol/mL). The resultant FG constructs were named 25%, 50%, 75%, and 100% 
FG, according to the fibrinogen dilution before thrombin activation.  
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5.2.2 Characterization of different FG concentrations 
5.2.2.1 Clotting time 
100 μL of different fibrinogen dilutions was mixed with 100 μL Thrombin-CaCl2 in a 96 well 
plate to make 25%, 50%, 75%, and 100% FG scaffolds. Change in the turbidity of the FG 
scaffold solution was immediately measured by a VersaMax UV-Vis spectrophotometer 
(Molecular Devices) at 550 nm wavelength (159). The clotting time was defined as the time at 
which the maximum value was reached in the absorbance curve. Three replicates of each FG 
scaffold concentrations were examined in this study. 
5.2.2.2 Scanning electron microscopy 
Three FG scaffolds constructed from 200 μL of different fibrinogen dilutions and 200 μL 
Thrombin-CaCl2 were used for scanning electron microscopy (SEM) analysis. After fixation in 
2.5% gluteraldehyde for 1 h and rinsing in PBS, FG scaffolds were dehydrated in increasing 
alcohol concentrations (30%, 50%, 70%, 90%, and 100%) for 15 min each, followed by 
hexamethyldisilazane for 1 h. Once hexamethyldisilazane was removed, the scaffolds were air-
dried for an hour. Each FG scaffold was coated with an ultra-thin gold layer containing a gold 
sputter coater for 2 min at 25 mA and observed under an SEM (JSM-6335F; Jeol USA, Inc). 
Two separate images of each scaffold were captured. Pore size diameter and thickness of fibrin 
fibers were measured for each image using image analysis software, Metamorph 7.6.2.0 
(Molecular Devices). 
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5.2.2.3 FG dissolution 
5.2.2.3.1  Wet weight measurement 
Different fibrinogen dilutions were mixed with an equal volume of thrombin-CaCl2 and injected 
into uncoated 24 well plate inserts with 8 μm pores at 200 μL FG/insert, and incubated at 37°C 
for 15 min to form hydrogels. The weight of each insert was measured before injection of the 
fibrinogen/thrombin solutions. Once the FG scaffolds had solidified, 500 μL PBS was added on 
top of each inserts, and the inserts were placed in a 24 well plate containing 1 mL PBS/well. 
After incubation at 37°C for 10 min, inserts were removed, PBS aspirated, surface PBS absorbed 
by a filter paper, and the initial weight of the hydrogels (W0) was recorded. FG hydrogels were 
re-weighed (Wt) every 2 days to estimate the wet weight fraction, which as defined as (W0 – 
Wt)/W0. Five replicates of each FG concentration were examined in this study. 
5.2.2.3.2  Protein dissolution 
The conditioned PBS from each well, in which the FG hydrogels were incubated, was also 
collected at the time of hydrogel wet weight measurement. The amount of the protein dissolved 
and released into the PBS was measured by UV-Vis spectroscopy (NanoDrop) at 278 nm, which 
measures the absorbance of the phenyl group of fibrinopeptide proteins. Fresh PBS was used as 
blank control. 
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5.2.3 AAV2-CMV-GFP in vitro transduction 
5.2.3.1 AAV2-CMV-GFP-loaded FG preparation 
Double-stranded AAV2-GFP with a cytomegalovirus promoter (dsAAV2-eGFP, hereunder 
referred to as AAV2-CMV-GFP) was prepared as previously described (120). The AAV2 
particles were packaged and purified using the adenovirus-free, triple plasmid transfection 
method. The titer (vector genome per milliliter [vg/mL]) was determined by viral DNA dot blot 
method (101). The stock AAV2-CMV-GFP titer was 3 x 1012 vg/mL. 
The AAV2-CMV-GFP vector stock was added to the various fibrinogen preparations 
(25%, 50%, 75%, and 100%) to obtain a final concentration of 6.25 x 1010 vg/mL. After 
vortexing for 3 min, the AAV2-CMV-GFP-loaded fibrinogen solutions were mixed with an 
equal volume of thrombin-CaCl2 and injected into uncoated 24 well plate inserts with 8 μm pores, 
at 200 μL/well. After gelation at 37°C for 15 min, pre-warmed 500 μL Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco)-1% penicillin-streptomycin (pen/strep, Gibco) was added to 
each insert. Three replicates were examined in this study. 
AAV2-CMV-GFP released from the AAV2-CMV-GFP loaded FGs and their direct 
transduction of mammalian cells were assessed over 21 days. HEK-293 cells (ATCC) were 
maintained in DMEM, 10% fetal bovine serum (Atlanta Biologicals), and 1% pen/strep at 37°C 
and 5% CO2. Each day, ~ 2.4 x 106 cells were seeded onto 24 well plates at a seeding density of 
100,000 cells/well and incubated for 24 h, after which the medium was changed to serum-free 
DMEM-1% pen/strep. Inserts containing AAV2-CMV-GFP-loaded FGs were placed into the 
wells of the 24 well plate seeded with HEK-293 cells and incubated for additional 24 h at 37°C. 
The medium was placed below and in the inserts to allow migration of AAV2-CMV-GFP from 
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the FG hydrogels to the seeded cells. Photomicrographs of GFP-expressing cells were taken 
daily using an Olympus DP71 camera and Nikon Eclipse TE2000-U microscope. All GFP 
images presented in Figure-5-4C – F had the contrast increased by the same value in Adobe 
Photoshop CS4 to improve the GFP signal for print. 
5.2.3.2 AAV2-CMV-GFP release from FG 
Each day, the conditioned serum free medium from each well was collected and preserved at -
80°C until analysis. The amount of AAV2-CMV-GFP released into the conditioned medium 
from AAV2-CMV-GFP-loaded scaffolds was quantified by quantitative polymerase chain 
reaction (qPCR). All PCRs containing 0.5 μL of conditioned medium in a total volume of 10 μL 
using a commercially available pre-prepared 2x Real-time TaqMan PCR Master Mix (Applied 
Biosystems). GFP-specific custom TaqMan forward (GTCCGCCCTGAGCAAAGA) and 
reverse (TCCAGCAGGACCATGTGATC) primers as well as FAM-labeled probes 
(CCCAACGAGAAGCG) were used. All qPCRs were performed with an ABI PRISM 7700 
Sequence Detection System (Applied Biosystems) according to the following program: 12 min at 
95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Three replicates of each 
experimental group were examined in this study. 
5.2.3.3 In vitro transduction of AAV2-CMV-GFP released from FG 
Transduction efficiency was quantified using flow cytometry and expressed as percentage of 
GFP-positive cells. Both AAV2-CMV-GFP-transduced and non-transduced control cells were 
trypsinized, washed, and resuspended in 400 μL of PBS with 1% bovine serum albumin and 2 % 
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paraformaldehyde (both from Fisher Scientific). Ten thousand events were collected using a BD 
Biosciences LSR II (BD Biosciences). The percentage of GFP-positive cells was determined by 
defining GFP-negative cells and gating out debris with Flow Jo 7.6.1 software (Tree Star, Inc.). 
Three replicates of each experimental group were examined in this study. 
5.2.4 AAV2-CMV-TGF-β1 in vitro transduction 
5.2.4.1 AAV2-CMV-TGF-β1-loaded FG preparation 
Double-stranded AAV2-TGF-β1 with a cytomegalovirus promoter (dsAAV2-TGF-β1, hereunder 
referred to as AAV2-CMV-TGF-β1) was prepared and purified as described above for AAV2-
CMV-GFP preparation. The stock AAV2-CMV-TGF-β1 titer was 2.5 x 1012 vg/mL. 
The AAV2-CMV-GFP and AAV2-CMV-TGF-β1 vector stocks were separately added to 
50% and 100% fibrinogen preparations to obtain a final concentration of 1.25 x 1011 vg/mL. 
After vortexting for 3 min, the AAV2-loaded fibrinogen solutions were mixed with an equal 
volume of thrombin-CaCl2 and injected into uncoated 6 well plate inserts with 8 μm pores, at 1 
mL/well. After gelation at 37°C for 15 min, pre-warmed 3 mL chondrogenic medium: High-
Glucose DMEM (Gibco) supplemented with 1% pen/strep (Gibco), 10-7 M dexamethasone 
(Sigma-Aldrich), 50 μg/mL L-ascorbic acid-2-phosphate (Sigma-Aldrich), 40 μg/mL proline 
(MP Biomedicals), and 1% ITS+ Premix (BD) was added to each insert. Three replicates of 50% 
and 100% AAV2-CMV-TGF-β1-loaded FGs were examined in this study against the 50% and 
100% AAV2-CMV-GFP-loaded FGs. 
AAV2-CMV-TGF-β1 released from the AAV2-CMV-TGF-β1-loaded FGs and their 
direct transductions of hBM-MSCs were assessed. The hBM-MSCs were obtained, maintained, 
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and characterized as previously described (57, 160). About 4.8 x 106 cells were seeded onto 6 
well plates at a seeding density of 200,000 cells per well and incubated for 24 h in their normal 
growth medium, after which the medium was changed to a chondrogenic medium. Inserts 
containing AAV2-CMV-GFP-loaded FGs and AAV2-CMV-TGF-β1-loaded FGs were placed 
into the wells of the 6 well plates seeded with hBM-MSCs and incubated for 24 h. The medium 
was placed below and in the inserts to allow migration of AAV2s from the FG hydrogels to the 
seeded cells. After the removal of the inserts, the cells were incubated for an additional 48 h at 
37°C. The conditioned serum free medium and hBM-MSCs from each well were collected 
separately and preserved at -80°C until analysis.  
5.2.4.2 In vitro transduction of AAV2-CMV-TGF-β1 released from FG 
The level of TGF-β1 expression from hBM-MSCs was assessed by determining the level of 
TGF-β1 in cell culture supernatant using a commercially available ELISA (R&D Systems, Inc) 
according to the manufacturer’s description, and using a CCL-64 mink lung epithelial growth 
inhibition assay as previously described with slight modification (161, 162). Briefly, the CCL-64 
cell line (ATCC, CRL-1573) was grown in DMEM, 10% FBS, and 1% pen/strep at 37°C in 5% 
CO2. CCL-64 cells were plated at 5,000 cells per well in 96 well plates and cultured in 100 μL of 
normal growth media for 3 h. The medium was then changed to 100 μL of serum-free DMEM-
1% pen/strep supplemented with 10% of conditioned media from hBM-MSC culture. The plates 
were incubated at 37°C in 5% CO2 for 24 h, and then 20 μL reconstituted XTT reagent from In 
Vitro Toxicology Assay Kit (Sigma-Aldrich) was added to each well for 2 h incubation. The 
absorbance at 450 nm was measured using VersaMax UV-Vis spectrophotometer. 
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Cartilage-specific gene expression was measured from hBM-MSCs by quantitative 
reverse transcription-polymerase chain reaction (qRT-PCR). Total RNA from the collected 
hBM-MSC samples was extracted using the RNeasy Mini Kit (Qiagen). The pre-designed human 
aggrecan and 18S TaqMan primers were purchased from Applied Biosystems. Human sox-9 
custom forward (TGACCTATCCAAGCGCATTACCCA) and reverse 
(ATCATCCTCCACGCTTGCTCTGAA) primers as well as FAM-labeled probed 
(AGGCCAACCTTGGCTAAATGGAGCA) were purchased from Integrated DNA Technologies 
(IDT). All samples contained 1 μL of extracted RNA in a total volume of 10 μL using a 
commercially available pre-prepared 2x Real-time TaqMan PCR Master Mix. All qRT-PCRs 
were performed with an ABI PRISM 7700 Sequence Detection System according to the 
following program: 12 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. 
Relative expression levels normalized to 18S were calculated using the 2-ΔCt method. 
5.2.5 Statistical analysis 
Data are expressed as mean ± standard error of mean. Statistical analysis was performed using 
independent samples t-test for comparison between two samples (Fig. 5-5), and one-way 
independent analysis of variance or one-way repeated measures analysis of variance with post 
hoc Tukey for multiple comparisons (Figs. 5-1 – 5-4) using Statistical Package for Social Studies 
(SPSS) 17.0 for Windows (IBM). The significance level was set as p < 0.05. 
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5.3 RESULTS 
5.3.1 Clotting time 
After activation of the different fibrinogen dilutions with thrombin-CaCl2, there was an 
immediate change in the turbidity of the solution. The clotting time, or the time of maximal 
turbidity, was dependent on the fibrinogen concentration (p < 0.001). Absorbance of the fibrin 
gel at 550 nm increased with time for all fibrinogen dilutions until it reached a plateau. The 
clotting time as a function of fibrinogen concentration is displayed in Figure 5-1. Clotting time of 
the 100% FG was significantly higher (p < 0.05) than the diluted (25%, 50%, and 75%) FG 
scaffolds. Although there was no significant difference in clotting time between the dilute FG 
scaffolds, there was an increasing trend in clotting time with increasing FG concentrations. 
Figure 5-1: Clotting time of FG hydrogels as a function of fibrinogen concentration 
Clotting time showed an increasing trend with increasing fibrin glue (FG) concentrations. Clotting time of 100% 
FG was statistically higher than diluted FGs. Bars represent mean ± standard error of mean; n  = 3. *p < 0.05 
compared with 100% FG. 
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5.3.2 SEM analysis of the FG hydrogel microstructure 
Figure 5-2: Scanning electron microscopy analyses of FG hydrogels 
(A-D) SEM photographs of freeze-dried 25%, 50%, 75%, and 100% FGs, respectively. (E) Pore size analysis of 
the FG cross-sections showed that the pore diameter of the 100% FG was significantly lower than those of the 
diluted FGs. (E) FG fiber thickness analysis showed an increasing trend with increasing concentration of FG. The 
fiber thickness of each group was statistically different from each other. Bars represent mean ± standard error of 
mean; n = 3. *p < 0.05, #p < 0.001. 
 
SEM analysis of pore size diameter of the FG scaffolds showed that all four scaffolds had pore 
size diameters ranging 50 – 1,200 nm. However, there was a denser, heterogeneous distribution 
of pores in the 100% FG (Fig. 5-2D) compared with the diluted FG hydrogels, which displayed a 
more homogeneous and larger pore size diameters (Fig. 5-2A – C). The pore size of the 100% 
FG was significantly smaller in diameter (p < 0.05) than those of the diluted FG scaffolds (Fig. 
5-2E). The fiber thickness of the scaffolds, also assessed by SEM, increased with increasing FG 
concentrations (Fig. 5-2F). The increases in fiber thickness were significant between scaffolds 
with different fibrinogen concentrations (p < 0.001). 
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5.3.3 In vitro dissolution of the FG hydrogels 
Analysis of in vitro FG dissolution in PBS showed a biphasic pattern (Fig. 5-3A). Wet weight 
fraction result showed that the dissolution rate is significantly affected by different 
concentrations of FG scaffolds (p < 0.001): 25% and 50% fibrinogen concentrations displayed a 
significantly higher rate of dissolution than 75% and 100% FG scaffolds. The first spike in 
dissolution occurred at day 2 for the 25% and 50% FG scaffolds, where the hydrogels lost ~35% 
and 15% of their initial weight, respectively. This was followed by a second spike at day 8, when 
the hydrogels lost ~80% of their initial weight. For the 75% and 100% FG scaffolds, the two 
spikes in dissolution occurred later at days 6 and 12, with loss of 20% and 90% of the initial 
weight for the respective time points. The pattern of protein released, observed by UV-Vis 
spectroscopy (Fig. 5-3B), correlates well with the wet weight fraction finding, by being 
significantly affected by the percentage of fibrinogen (p < 0.001). As well, the biphasic pattern of 
absorbance peaks that reflects most weight dissolution into the conditioned PBS can be noted. 
Figure 5-3: In vitro FG dissolution 
(A) Wet weight fraction analysis and (B) absorbance at 278 nm, reflecting the amount of phenyl group of 
fibrinopeptide proteins dissolved in the conditioned PBS, showed a biphasic dissolution pattern for all FGs. Data 
markers represent mean ± standard error of mean; n = 5. *p < 0.05 between 25% and 50% FGs and 75% and 100% 
FGs. 
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5.3.4 Quantification of the amount of released AAV2-CMV-GFP from FG hydrogels 
The amount of AAV2-CMV-GFP released into the conditioned media from the AAV2-CMV-
GFP-loaded FG scaffolds is significantly affected by different concentrations of FG scaffolds (p 
< 0.001), and also displays a biphasic pattern (Fig. 5-4A). The spikes in the amount of AAV2-
CMV-GFP released into the media occurred at day 2 and 9 for 25% and 50% scaffolds. In 
contrast, the spikes in the amount of AAV2-CMV-GFP released into the media occurred at day 2 
and 15 for 75% and 100% FG scaffolds. Approximation of the area under the curves in Figure 5-
4A suggests that the vector genomes of AAV2-CMV-GFP released into the media from 75% and 
100% FG scaffolds were lower than that of 25% and 50% FG scaffolds. 
Figure 5-4: In vitro characterization of AAV2-CMV-GFP-loaded FG scaffolds 
(A) Vector genomes (vg) of AAV2-CMV-GFP released into 1 mL of conditioned media and (B) percentage of 
GFP-positive HEK-293 cells show biphasic AAV2-CMV-GFP release and corresponding spikes in percentage of 
GFP-positive cells. Data markers represent mean ± standard error of mean; n =3. *p < 0.05 between 25% and 50% 
FGs and 75% and 100% FGs. (C-F) Fluorescent and bright-field photomicrographs of HEK-293 cells incubated 
with AAV2-CMV-GFP-loaded 25%, 50%, 75%, and 100% FGs at day 8 correlates with the quantitative findings 
in A and B. 
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5.3.5 Quantification of mammalian cell transduction efficiency of released AAV2-
CMV-GFP 
The percentage of GFP-positive cells from transduction of AAV2-CMV-GFP released into the 
conditioned media from the AAV2-CMV-GFP-loaded FG scaffolds is also significantly affected 
by different concentrations of FG scaffolds (p < 0.001), and showed a biphasic pattern (Fig. 5-
4B). This pattern is similar to those of the FG dissolution (Fig. 5-3) and AAV2-CMV-GFP 
release (Fig. 5-4A). FG scaffolds with 25% and 50% fibrinogen concentrations yielded 
significantly higher percentage of GFP-positive cells than the 75% and 100% FG scaffolds. 
There were spikes in the percentage of GFP-positive cells at days 1 and 8 for all FG scaffolds, 
which correlate with the biphasic release pattern of high amounts of AAV2-CMV-GFP at these 
time points (Fig. 5-4A). Although 75% and 100% FG scaffolds showed similar biphasic spikes in 
the percentage of GFP-positive cells, the response was significantly lower compared with 25% 
and 50% FG scaffolds. Photomicrographs of GFP-expressing cells taken daily confirmed 
quantitative findings by flow cytometry (Fig. 5-4C – F). 
5.3.6 Quantification and functional analysis of TGF-β1 expression from hBM-MSCs 
transduced with released AAV2-CMV-TGF-β1 
The amount of TGF-β1 synthesized by hBM-MSCs and released into the conditioned medium is 
significantly affected by different concentrations of FG scaffolds (Fig. 5-5A, B). Cells incubated 
with 50% FG loaded with AAV2-CMV-TGF-β1 made 2.5-fold more active TGF-β1 than those 
incubated with 100% FG loaded with AAV2-CMV-TGF-β1 (p = 0.017, Fig. 5-5A). As well, the 
conditioned medium from the hBM-MSC culture that was incubated with the 50% FG loaded 
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with AAV2-CMV-TGF-β1 resulted in greater inhibition of CCL-64 cell proliferation (Fig. 5-5B), 
measured via mitochondrial activity (p = 0.002). The different concentrations of AAV2-CMV-
TGF-β1-loaded FG scaffolds also affected the cartilage-specific gene expression of the hBM-
MSCs (Fig. 5-5C). Human sox-9 and aggrecan mRNA expressions were significantly higher for 
50% FG versus 100% FG (p = 0.049 and p = 0.009, respectively). All the results were 
normalized against values from AAV2-CMV-GFP-loaded FG scaffolds of the same percentage 
fibrinogen concentration to account for the effects of viral transduction, FG, and endogenous 
TGF-β1 production by hBM-MSCs. 
Figure 5-5: In vitro characterization of AAV2-CMV-TGF-β1-loaded FG scaffolds 
(A) Mean fold amount of active TGF-β1 released into the conditioned media showed increased production of TGF-
β1 from hBM-MSCs incubated with 50% FG. (B) Mean fold XTT absorbance measurement from CCL-64 cells 
showed higher TGF-β1-mediated growth inhibition in samples incubated with conditioned media from 50% FG. 
(C) Mean fold human sox-9 and aggrecan mRNA expressions from hBM-MSCs incubated with AAV2-CMV-
TGF-β1-loaded FG scaffolds showed increased expression of relevant chondrogenic genes in cells incubated with 
50% FG. Data were normalized against values from AAV2-CMV-GFP-loaded FG scaffolds of the same 
percentage fibrinogen concentration to account for the effects of viral transduction, FG, and endogenous TGF-β1 
production by hBM-MSCs. Bars represent mean ± standard error of mean; n = 3. *p < 0.05 between 50% and 
100% FGs. 
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5.4 DISCUSSION 
Tissue engineering scaffolds allow for the delivery of cells or diffusible factors that can act 
locally to promote tissue regeneration (163, 164). The combination of gene therapy and tissue 
engineering offers the potential to direct progenitor cells’ proliferation and differentiation into 
functional tissue replacement (53). We have previously shown that hMSCs transduced with 
AAV-TGF-β1 improved the in vivo cartilage repair when the ex vivo transduced cells were 
implanted into osteochondral defects of athymic rats (42). However, in an effort to move beyond 
ex vivo gene transfer, the current focus of the project is on in situ delivery of therapeutic 
transgenes, such as TGF-β1, directly to host MSCs residing in cartilage wounds using 
biodegradable scaffolds. This strategy can be thought of as “augmenting” microfracture, which is 
an accepted human clinical standard for treatment of full-thickness cartilage defects (165). The 
goal of this strategy is to induce localized exogenous transgene expression in repair/progenitor 
cells infiltrating into the scaffold for sustained release of these factors at the site of injury. 
Strategies that combine scaffolds, drug delivery technology, and gene therapy have the potential 
to provide more effective tissue regeneration with significant improvements on safety and cost 
issues compared to currently available therapies.  
Although numerous novel synthetic and natural polymers have been investigated for 
cartilage tissue engineering studies (140, 153, 154), usage of an FDA-approved and autologous 
biomaterial as an AAV2-releasing scaffold can accelerate the transition of basic science research 
into human clinical studies. FG is a biomaterial widely used in clinical practice and tissue 
engineering applications. As well, dilute FG has been successfully used to treat cartilage wounds 
in a pilot human clinical study (152). However, studies on its use as a delivery scaffold for gene 
vectors are limited, and only adenovirus delivery has been investigated for delivery of viral 
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vectors (55). FG has been investigated as a delivery scaffold for controlled release of adenovirus 
in a rabbit ear ulcer model (156) and for perivenous adventitial gene transfer (158), and was 
shown to provide enhanced in vivo transgene expression over adenovirus transduction without 
FG scaffold. For cartilage tissue engineering purposes, FG scaffolds with non-viral copolymer-
protected polyethylenimine-DNA vectors achieved sustained release of the gene over 20 day 
period and successful in vitro transfection of human keratinocytes and rabbit articular 
chondrocytes (157). 
Nonetheless, FG formulation for AAV2 delivery has not been optimized. The 
fibrinogen/thrombin concentration in the FG preparation has been shown to affect the structural 
properties of the scaffold, and in turn influence the proliferation rate and morphology of hMSCs 
(155). Therefore, alterations in FG scaffold microstructure can influence its function as a 
delivery scaffold for AAV2. The aim of the current study was to assess, in vitro, the structural 
characteristics of FG hydrogels containing varying fibrinogen concentrations, their AAV2-
particle release kinetics, and subsequent transgene expression in target cells for articular cartilage 
tissue engineering. 
Undiluted 100% FG scaffold had longer gelation time compared with diluted scaffolds, 
which may be explained by data from SEM analysis, which showed that 100% FG scaffolds 
formed a denser scaffold with smaller pore sizes and thicker fibrin fibers than diluted FG 
scaffolds. In contrast, diluted FG scaffolds had a more open fibrin network, which was reflected 
by their shorter clotting times. Consistent with another finding (155), diluted FGs had a more 
homogenous structure than undiluted 100% scaffold. 
FG scaffolds dissolved over time in PBS, which was shown by the decrease in the wet 
weight over time and by the change in absorbance measurements of the phenyl group of the 
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fibrinopeptide over time. Dissolution of the FG scaffolds coincided with the amount of AAV2-
CMV-GFP released into the conditioned media. In addition, both the dissolution of the scaffold 
and the amount of AAV2-CMV-GFP released into the media occurred in a biphasic burst fashion, 
consistent with a typical hydrogel bulk-degradation pattern. The burst release pattern of AAV2-
CMV-GFP was similar to the percentage of GFP-positive HEK-293 cells. There were more GFP-
positive cells when a greater amount of AAV2-CMV-GFP was released into the media. Both the 
amount of AAV2-CMV-GFP released and the number of GFP-positive cells is higher in wells 
with 25% and 50% FG scaffolds than in those with 75% and 100% FG scaffolds. In addition to 
dissolution pattern of the FG scaffold, the more open fibrin network of the 25% and 50% FG 
scaffolds may contribute to greater release of AAV2-CMV-GFP and the higher percentage of 
GFP-positive cells compared with 75% and 100% FG scaffolds. These in vitro studies showed 
that commercial strength 100% as well as 75% FGs are less efficient at releasing AAV2 particles, 
and that dilute 25% and 50% FGs are more effective. Viral particles released from dilute FGs 
retained the ability to transducer HEK-293 cells up to 17 days in vitro. 
In contrast to our findings with AAV2, a previous study investigating different 
concentrations of FG scaffold loaded with adenovirus had achieved optimal viral releasing 
properties with the higher fibrinogen concentration (166). However, this was observed with 
adenovirus vector and with a diluted thrombin concentration. Compared with adenovirus, AAV 
is much smaller and has the advantages of improved safety profile and longer transgene 
persistence (47). In addition, lower thrombin concentration decreases the rate of fibrin cross-
linking (55). Since in vivo FG decomposition will be accelerated via plasmin-mediated fibrin 
degradation in addition to diffusion-mediated dissolution, FGs prepared with undiluted thrombin 
are more likely to persist and release AAV2 particles longer for animal or human applications. 
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Although many more dilutions of FG at smaller increments could be studied to further 
assess the AAV2 release kinetics, especially with lower concentrations of FG, the four dilutions 
were chosen to support the goal of evaluating FG concentrations potentially useful for in vivo 
clinical applications. As well, FG dilutions of 25% approach the lower limit to achieve a 
clinically functional scaffold structure (166). For this reason, 50% and 100% FGs were chosen 
for subsequent studies with AAV2-CMV-TGF-β1. 
As our ultimate goal is to develop a localized AAV2 delivery system for cartilage tissue 
engineering, we further explored the concentrations of 50% and 100% FGs for delivery of AAV2 
encoding for a therapeutic gene useful for cartilage regeneration. Transforming growth factor-β1 
(TGF-β1) has long been shown to consistently induce BM-MSC chondrogenesis in vitro 
(57, 167). We also have previously shown that implantation of AAV2-CMV-TGF-β1-transduced 
hMSCs into osteochondral defects has improved cartilage repair in vivo (42). Therefore, we 
compared AAV2-CMV-TGF-β1 delivery from the 50% and 100% FGs to hBM-MSCs in vitro. 
The studies on FG scaffold delivery of therapeutic AAVs versus reporter gene AAVs, especially 
for their chondrogenic effects, have been limited to date (166). hBM-MSCs cultured with 50% 
FG-AAV2-CMV-TGF-β1 construct had higher concentration of active TGF-β1, which resulted in 
greater inhibition of CCL-64 cell proliferation, and higher cartilage-specific gene expression 
levels in tranduced hBM-MSCs. 
5.5 CONCLUSIONS 
In summary, we have demonstrated that varying the fibrinogen concentrations in FG constructs 
changes the structural and functional characteristics of the scaffold for gene delivery. Diluting 
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the fibrinogen concentration yields a scaffold with a network of larger pores and thinner fibers, 
which reduces entrapment and subsequently enhances the release of AAV2 particles. Lower 
concentration FG scaffolds have also been shown to promote greater proliferation of hMSCs, 
which are the principal cell types recruited for in situ chondrogenesis (155). Therefore, 
implantation of diluted FG scaffolds containing bioactive AAV2 vectors have the potential to 
improve articular cartilage regeneration and be translated for clinical cartilage tissue engineering. 
Further in vivo studies are planned using small and large animal models to validate the enhanced 
repair potential of diluted FG scaffolds with therapeutic AAV2-TGF-β1 for localized in situ 
cartilage tissue engineering before translation into the clinical setting. 
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6.0  INTERLEUKIN-1BETA-MEDIATED INHIBITION OF HUMAN 
MESENCHYMAL STEM CELL CHONDROGENESIS IS BLUNTED BY ADENO-
ASSOCIATED VIRUS GENE TRANSFER OF INTERLEUKIN-1 RECEPTOR 
ANTAGONIST AND TRANSFORMING GROWTH FACTOR-BETA1 
6.1 INTRODUCTION 
Articular cartilage plays the essential role of forming a smooth surface between two bones, 
permitting frictionless joint motion. It is mainly composed of chondrocytes, as well as collagen 
type II and aggrecan that form a dense and avascular extracellular matrix (ECM). Due to the 
dense and avascular nature of ECM, the healing capacity of articular cartilage once damaged, is 
severely limited. Cartilage injuries, from trauma or degeneration, lead to debilitating 
osteoarthritis, often regardless of treatment status.  
Microfracture is a commonly used surgical technique to promote cartilage repair (168). 
This technique involves perforation of the subchondral bone to allow bone marrow contents to 
access and fill the defect and undergo chondrogenic differentiation. The bone marrow contents 
include bone marrow-derived mesenchymal stem cells (MSCs) and various growth factors. 
Numerous studies have shown successful MSC differentiation into the chondrogenic phenotype 
using various growth factors in a controlled in vitro environment with pre-defined chondrogenic 
differentiation media (61). The microfracture technique resulted in improved cartilage repair in 
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in vivo studies as well; however, the remodeled cartilage remains inferior to the native articular 
cartilage in terms of matrix composition and biomechanical quality (169). Microfracture, 
nonetheless,  remains popular due to its convenience and minimally invasive nature (168).  
 The altered homeostatic environment of the diseased joint may be responsible for the 
inconsistency between the in vitro and in vivo results of MSC chondrogenesis (80). In contrast to 
a healthy joint or a pre-defined in vitro environment, catabolic/inflammatory mediators are 
upregulated in diseased joints or from the surgical intervention itself, further impairing the ability 
of cartilage repair (170, 171). Indeed, addition of inflammatory cytokines, such as interleukin 
(IL)-1β and tumor necrosis factor (TNF)-α, in pre-defined chondrogenic media inhibited 
chondrogenic differentiation of MSCs in a dose-dependent manner (71, 80). When the cytokine 
actions were blocked using antagonist molecules in vitro, the inhibitory effect on chondrogenesis 
was restored to a certain extent (80).  
The anti-inflammatory molecules used in this study include IL-1 receptor antagonist 
protein (IRAP) and transforming growth factor (TGF)-β1. IRAP is a small 20 – 25 kDa secreted 
protein with no known agonist function (74). It competitively inhibits IL-1 signaling via 
competitive inhibition of IL-1 ligand and receptor interactions (73). TGF-β1, on the other hand, is 
a well-established anabolic growth factor that induces MSC chondrogenesis, and is often 
included in chondrogenic differentiation media (42, 57). In addition to its anabolic functions, 
TGF-β1 has also been shown to decrease the catabolic activity of inflammatory cytokines in vitro 
and in vivo (64). However, although these anti-inflammatory strategies are straightforward, the in 
vivo efficacy is limited by the poor pharmacokinetics of the small molecule and the need for 
sustained high concentrations. 
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 To overcome this limitation, genetic modification of MSCs has been explored for 
sustained delivery of the bioactive factors. Numerous vector carriers, such as adenovirus, 
lentivirus, and retrovirus, have been studied for gene transfer; nonetheless, significant safety 
concerns associated with these viruses limit their application to clinical gene therapy (123). 
Adeno-associated virus (AAV), in contrast, is a non-pathogenic virus that is already used in 
numerous human clinical trials (47, 119). AAV transduction of MSCs has also been extensively 
studied by us and others (16, 42, 108). 
 In the current study, we investigated the chondrogenic differentiation of AAV-transduced 
MSCs in the presence of inflammatory cytokines in vitro. IRAP and TGF-β1 molecules were 
overexpressed in the MSCs via AAV-gene transfer. The aim of the study was to test the 
hypothesis that chondrogenic potential of MSCs will be enhanced by using AAV-encoding for 
anti-catabolic factors, such as IRAP and TGF-β1. 
6.2 METHOD 
6.2.1 hMSC cell culture 
Human MSCs were obtained, processed, and maintained as previously described (57). Briefly, 
femoral bone marrow reaming tissues were obtained according to an exempt IRB-approved 
protocol at the University of Pittsburgh for discarded tissue. The bone marrow was minced, 
washed in phosphate buffered saline (PBS, Gibco), and vortexed. Then the cell suspension was 
passed through a cell strainer, loaded onto Histopaque-1077 density gradient (Sigma-Aldrich), 
and centrifuged at 400 x g for 30 min at 4°C to fractionate. Mononucleated cells were collected 
 95 
and cultured in MSC growth media composed of Minimum Essential Medium Alpha (α-MEM, 
Gibco), 16.5% fetal bovine serum (FBS, Atlanta Biologicals), 1% penicillin-streptomycin 
(pen/strep, Gibco), and 2 mM L-glutamine (Invitrogen). Freshly isolated cells were allowed to 
adhere to the tissue culture flask for 5 – 7 days at 37°C and 5% CO2 prior to media change. Cells 
were passaged after 10 days of initial plating via detaching with 0.25% trypsin (Invitrogen) and 
replating at 100 cells/cm2 density. Medium was changed every 3 – 4 days. The cells were 
expanded for two passages, when hMSCs reached 70% confluence, and then frozen in FBS, 10% 
dimethyl sulfoxide (DMSO, Sigma). For the experiments in this study, the frozen passage 2 
hMSCs were thawed and grown in MSC growth media for 8 days, with media change at days 4 
and 6. 
6.2.2 AAV preparation and hMSC transduction 
Double-stranded serotype 2 AAVs encoding for enhanced green fluorescence protein (GFP) with 
cytomegalovirus (CMV) promoter (AAV-GFP), human IRAP with CMV enhancer/beta-actin 
(CB) promoter (AAV- hIRAP), and human TGF-β1 with CMV promoter (AAV-TGF-β1) were 
prepared and purified as previously described (120). The vector titers, determined using viral 
DNA dot blot method (101), were 6 x 1012 vector genomes (vg)/mL for AAV-GFP, 2 x 1012 
vg/mL for AAV-hIRAP, and 1 x 1012 vg/mL for AAV-TGF-β1. AAV transductions were 
performed when the thawed passage 2 hMSCs reached 80% confluence in T-225 flasks at a 
50,000 – 100,000 vg/cell concentration in 10 mL of serum and antibiotic-free α-MEM. The 
untransduced control cells were treated with 10 mL serum and antibiotic-free α-MEM only. 
After one hour incubation, 20 mL of hMSC growth media was added to the tissue culture flasks. 
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Table 6-1: Experimental conditions 
Groups AAV transgene Cytokine Stimulation Chondrogenic Media 
1 Untransduced CTRL None CM + TGF-β12 IL-1β CM + TGF-β1 + IL-1β
3 GFP None CM + TGF-β14 IL-1β CM + TGF-β1 + IL-1β
5 hIRAP None CM + TGF-β16 IL-1β CM + TGF-β1 + IL-1β
7 TGF-β1 
None CM 
8 IL-1β CM + IL-1β
6.2.3 Chondrogenic pellet culture 
Fourty-eight hours post-AAV-transduction, MSCs were pelleted for chondrogenic culture as 
previously described (42, 57, 121). Briefly, AAV-transduced MSCs in tissue culture flasks were 
washed, trypsinized, and washed again in PBS and counted. The cells were divided into 8 groups 
(Table 6-1) and were separately aliquoted in 15-mL polypropylene conical tubes at a density of 
2.5 x 105 hMSCs in 0.5 mL of chondrogenic media. The composition of basal chondrogenic 
media (CM + TGF-β1) are high-glucose Dulbecco’s Modified Eagle Medium (DMEM, Gibco), 
with 1% penicillin-streptomycin (Gibco), 10-7-M dexamethasone (Sigma-Aldrich), 50-μg/mL L-
ascorbic acid-2-phosphate (Sigma–Aldrich), 40-μg/mL proline (MP Biomedicals, Solon), and 
1% BD™ ITS + Premix (Becton-Dickinson), and 10 ng/mL human TGF-β1 (R&D Systems). For 
the cytokine groups, 10 ng/mL of human IL-1β (R&D Systems) were supplemented in CM + 
TGF-β1 media (CM + TGF-β1 + IL-1β). Of note, TGF-β1 was excluded from the chondrogenic 
media for chondrogenic culture of hMSC transduced with AAV-TGF-β1 (CM and CM + IL-1β). 
The aliquots were centrifuged at 500 x g for 5 min, after which the tubes with loose caps were 
incubated at 37°C and 5% CO2. The media was refreshed every 2-3 days. 
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6.2.4 Longitudinal transgene expression 
The transgene expression from AAV-transduced hMSCs over the chondrogenic culture period 
was assessed by detecting GFP expression by live fluorescence with a MVX-10 MacroView 
Systems stereomicroscopy equipped with DP71 camera (both from Olympus), and determining 
the level of hIRAP in conditioned media at different time points using a commercially available 
ELISA (R&D Systems) according to the manufacturer’s description. The GFP images in Fig. 1A 
had the contrast increased by the same value in Adobe Photoshop CS4 to improve image contrast 
for print. 
6.2.5 Gross and histological assessments of hMSC pellets 
At the end of 21 days of chondrogenic culture, hMSC pellets were grossly assessed with 
stereomicroscopy and DP71 camera. The pellet area was measured using ImageJ (NIH). The 
pellets were subsequently fixed and processed for histological analyses using Safranin O-Fast 
green staining for sulfated glycosaminoglycan (GAG) according to standard protocols.  
6.2.6 Biochemical analyses of hMSC pellets 
Chondrogenic hMSC pellets were also collected for biochemical analyses. Each pellet was 
papain-digested overnight in a 60°C shaking water bath (200 RPM) in 0.25 mL papain buffer. 
The composition of papain buffer was the following: 50 mM sodium phosphate (Sigma-Aldrich), 
5 mM Ethylenediaminetetraacetic acid (EDTA, Gibco), 5 mM cysteine HCl (Sigma-Aldrich), 
and 0.5 mg/mL papain (Sigma-Aldrich). The total GAG content from the digested pellets was 
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quantified with the dimethylmethylene blue (DMMB) assay using VersaMax UV-Vis 
spectrophotometer (Molecular Devices) as previously described (57). The DNA content was also 
quantified with Quant-iT™ PicoGreen® dsDNA Reagent and Kits (Molecular Probes) and a 
VICTOR™ X3 Multilabel Plate Reader (Perkin Elmer) per manufacturer’s protocol. The GAG 
content of the pellets was normalized by dividing the DNA from the GAG contents. 
6.2.7 Statistical analyses 
All the statistical data analyses were performed using Statistical Package for Social Studies 
(SPSS) 17.0 for Windows (IBM), with the significance level set as p < .05 unless otherwise 
noted. Shapiro-Wilk and Levene’s tests were used to test the assumptions of parametric data. The 
longitudinal IRAP transgene expression levels in conditioned media were analyzed using two-
way mixed analysis of variance (ANOVA), with time as repeated measure and cytokine as 
independent variables (Fig. 1B). Pellet sizes and GAG contents were analyzed using two-way 
independent ANOVA with the AAV constructs and cytokine as independent variables (Figs. 2B, 
3B, and 4B) and post hoc Tukey when there was a significant effect of AAV construct on the 
outcome variables (Figs. 3B and 4B). Student’s t-test was used when the interaction effects were 
significant from the two-way ANOVAs to analyze the effect of cytokine stimulation.  
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6.3 RESULTS 
 
Figure 6-1: Longitudinal transgene expression from AAV-transduced hMSC pellet culture 
(A) GFP-expression from AAV-GFP transduced hMSCs at 7, 14, and 21 days of chondrogenic culture, with and 
without IL-1β. (B) hIRAP concentration detected from conditioned culture media from AAV-hIRAP transduced 
hMSCs at various time points of chondrogenic culture with and without IL-1β. n = 2 – 3/group. *p < .007 between 
CTRL and IL-1β at each time points.  
6.3.1 Longitudinal transgene expression 
Robust GFP transgene expression was observed in AAV-GFP transduced hMSC chondrogenic 
pellets throughout the 21 day culture period (Fig. 6-1A). The IL-1β stimulated AAV-GFP group 
pellets, while smaller in size, showed brighter GFP signal than the control AAV-GFP group 
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pellets at all time points. No GFP-signal was observed from the untransduced control and AAV-
hIRAP or AAV-TGF-β1 transduced pellets (Data not shown). Detectable levels of hIRAP 
transgene product were seen in AAV-hIRAP transduced hMSC chondrogenic pellets throughout 
the 21 day culture period (Fig. 6-1B). There was a significant main effect of time on the hIRAP 
concentration (p < .001), with gradual decrease in the transgene expression over time.  Although 
there was no significant effect of cytokine stimulation (p = .276), the interaction effect between 
the time and cytokine stimulation was significant (p = .010). Hence, the cytokine effect was 
further explored. There was a significant effect of cytokine stimulation at days 14, 17, and 21 on 
hIRAP production (ps < .007): hMSC pellets cultured in the presence of IL-1β produced more 
hIRAP than those cultured without IL-1β. No hIRAP was detected from the untransduced control 
and AAV-GFP or AAV-TGF-β1 transduced pellets (Data not shown). 
Figure 6-2: Macroscopic analysis of AAV-hIRAP-transduced hMSCs at 21 days of chondrogenic culture 
(A) Representative images of hMSC pellets from untransduced, AAV-GFP, and AAV-hIRAP groups with and 
without IL-1β. (B) Area analysis of the pellets hMSC pellets from untransduced, AAV-GFP, and AAV-hIRAP 
groups with and without IL-1β. Mean fold pellet area was normalized against the area from untransduced no 
cytokine treated pellets. n = 2 – 3/group. *p < .05 between CTRL and IL-1β. 
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6.3.2 hMSC pellet area evaluation 
Macroscopic images of the hMSC pellets were taken at chondrogenic culture day 21 (Figs. 6-2 
and -3). For the AAV-hIRAP pellet area analysis (Fig. 6-2B), there was a significant main effect 
of cytokine (p < .001). There was no significant effect of AAV constructs (p = .158); however, 
the interaction effect between the AAV construct and cytokine stimulation was significant (p = 
.001). When the cytokine effect on each of the AAV groups was further explored, the areas of 
hMSC chondrogenic pellets were significantly decreased by IL-1β stimulation for untransduced 
control and AAV-GFP groups (p = .025 and p = .024, respectively). On the other hand, the effect 
of cytokine stimulation for AAV-hIRAP group was not significant.  
 
Figure 6-3: Macroscopic analysis of AAV-TGF-β1-transduced hMSCs at 21 days of chondrogenic culture 
(A) Representative images of hMSC pellets from untransduced, AAV-GFP, and AAV-hIRAP groups with and 
without IL-1β. (B) Area analysis of the pellets hMSC pellets from untransduced, AAV-GFP, and AAV-hIRAP 
groups with and without IL-1β. Mean fold pellet area was normalized against the area from untransduced no 
cytokine treated pellets. n = 3 – 4/group. *p < .05 between CTRL and IL-1β. 
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For the AAV-TGF-β1 transduced hMSC pellets (Fig. 6-3B), their areas were significantly 
affected by both the AAV constructs and cytokine stimulation (ps < .001). As well, their 
interaction effect was significant (p < .001). Post hoc Tukey analysis showed that all three AAV 
construct groups were significantly different from one another (ps < .001 for all comparisons).   
The cytokine effect was further explored as well: the areas of hMSC chondrogenic pellets were 
significantly decreased by IL-1β stimulation for the untransduced control and AAV-GFP groups 
(ps < .001), but not for the AAV-TGF-β1 transduced hMSC pellets.   
6.3.3 hMSC glycosaminoglycan content 
GAG contents of hMSC pellets were stained, measured and calculated after 21 days of 
chondrogenic culture (Fig. 6-4). Via Safranin-O Fast Green staining (Fig. 6-4A), the 
untransduced control hMSC pellets underwent the best chondrogenesis, while the untransduced 
IL-1β stimulated hMSC pellets performed the worst. Comparing the non-IL-1β stimulated 
control groups, the AAV-GFP and AAV-hIRAP transductions reduced the chondrogenic 
potential of hMSCs, with AAV-hIRAP having greater effect than the AAV-GFP. On the other 
hand, when the pellets were treated with IL-1β, AAV-hIRAP transduction rescued the IL-1β-
mediated inhibition of hMSC chondrogenesis, while AAV-GFP had no effect.  
 When the GAG content was quantified via biochemical analyses (Fig. 6-4B), there were 
significant main effects of AAV constructs (p = .031) and cytokine stimulation (p < .001). As 
well, the interaction effect between the two main effects was significant (p = .001). Post hoc 
analysis of the three AAV constructs revealed that there was a significant difference between 
AAV-GFP and AAV-hIRAP pellets (p = .009), but no differences between any other pellets. 
When the cytokine effect for each AAV constructs was analyzed, the IL-1β stimulation 
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significantly decreased the GAG content for the untransduced control (p = .014) and AAV-GFP 
groups (p = .001), but not for the AAV-hIRAP groups.   
Untransduced AAV-GFP AAV-hIRAP
CTRL
IL-1β
B
A
*
*
Figure 6-4: GAG content of AAV-hIRAP transduced hMSC pellets at 21 days of chondrogenic culture 
(A) Representative Safranin O-Fast green images of hMSC pellets from untransduced, AAV-GFP, and AAV-hIRAP 
groups with and without IL-1β. (B) GAG content analysis of the pellets hMSC pellets from untransduced, AAV-
GFP, and AAV-hIRAP groups with and without IL-1β. Mean ratio GAG content was normalized against that of the 
untransduced no cytokine treated pellets. n = 2 – 3/group. *p < .05 between CTRL and IL-1β.  
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6.4 DISCUSSION 
Injuries to avascular articular cartilage, with its limited repair potential, frequently progress to 
debilitating osteoarthritis, which is a significant clinical problem with respect to its prevalence 
and cost in healthcare dollars (4, 5, 8). Numerous approaches are investigated to promote 
cartilage restoration; of which accessing of bone marrow derived MSCs via microfracture is a 
popular technique. These MSCs subsequently undergo chondrogenic differentiation; however, 
they often result in fibrocartilageneous phenotype with inferior matrix composition and 
biomechanical properties. It has been shown that inflammatory cytokines, generally present in 
the joint due to the disease/injury state or due to the surgical intervention, limit the chondrogenic 
differentiation potential of MSCs (71, 80). Therefore, the anti-catabolic side of the MSC 
chondrogenesis strategy is increasingly recognized to be important and warrants additional 
investigation.   
IL-1 is the major inflammatory cytokine in injured joints and plays a pivotal role in 
osteoarthritis pathogenesis (172, 173). Numerous studies have investigated the inhibition of this 
cytokine as a treatment strategy against osteoarthritis progression (81). Of these approaches, 
interleukin-1 receptor antagonist (IRAP) that inhibits IL-1 at the cell receptor level has been a 
popular choice. A recombinant human IRAP is approved for human clinical use for subcutaneous 
injection treatment of rheumatoid arthritis (128). IRAP has been shown to have beneficial effect 
against symptoms and structural changes of articular cartilage degeneration of osteoarthritis 
models in a myriad of in vitro and in vivo studies (74, 172, 174, 175). As well, when IRAP was 
injected into the joint during a randomized controlled pilot trial, there was a reduction of knee 
pain and improvement of joint function in an acute injury setting (128). However, studies on 
using IRAP during MSC chondrogenesis or cartilage regeneration are limited (80, 176). 
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TGF-β is the most extensively examined anabolic growth factor for hMSC induction into 
the chondrogenic phenotype, especially the TGF-β1 isoform (42, 57). In addition to its anabolic 
effect, TGF-β1 has been shown to counteract the inflammatory cytokines during chondrogenesis 
to a certain extent (71). Hence, treatment of MSCs with IRAP and TGF-β1 may enhance their 
chondrogenic differentiation in a disease/inflammatory state. However, appreciable and 
prolonged stimulation of these factors may be unachievable in a clinical setting with 
conventional protein applications due to their short half-lives, need for high repetitive dosing, 
and costly purification process. Therefore, AAVs were utilized to deliver genes encoding for 
these bioactive factors to MSCs for their production in situ. 
The current study investigated ex vivo genetic manipulation of MSCs. We, however, 
recognize that this approach faces high regulatory barriers for clinical translation. Additionally, 
obtaining and expanding MSCs prolongs the time before treatment. Therefore, we have also 
explored other ways to apply AAV gene therapy, such as by direct intra-articular injection and 
by use of biodegradable scaffolds for release and delivery of bioactive AAVs to host MSCs 
within cartilage wounds for transduction in situ (47, 108, 140, 152-154). Hence, this in vitro 
study investigating the chondrogenesis of AAV-IRAP or AAV-TGF-β1 transduced hMSCs 
would provide a basis for a future in vivo study using these alternative strategies. 
In a three-dimensional chondrogenic pellet culture, AAV-transduced MSCs resulted in 
detectable levels of transgene expression throughout the 21 day culture period. Transgene 
expression from the IL-1β stimulated pellets was noted to be higher, with statistically significant 
increases on latter three 14, 17, and 21 day time points. This upregulation of AAV-transgene 
expression following cytokine treatment has also been noted by another study (46). The authors 
postulated its mechanism to be due to inflammation-induced cell proliferation or due to enhanced 
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activation of the CMV promoter via NF-κB signaling pathway. In the present study when the 
DNA content per pellet was quantified, it was significantly increased with IL-1β treatment in the 
AAV-GFP (p = .002), but not for the AAV-hIRAP transduced hMSC pellets (p = .829; Data not 
shown). Hence, IL-1β stimulated more cell proliferation in the AAV-GFP group, but this was 
blunted by IRAP treatment, making the latter IL-1β activation of promoter the more likely 
explanation. This IL-1β upregulation of its inhibitor is a highly advantageous mechanism to 
prevent IL-1β-mediated catabolic effects. 
The area measurements of hMSC chondrogenic pellets showed that IL-1β has a negative 
effect on the pellet size. However, this negative effect was successfully blunted with the 
treatment of hMSCs with AAV-hIRAP or AAV-TGF-β1. Of note, AAV-GFP transduction 
limited the chondrogenic potential of hMSCs compared to those of the untransduced control, 
suggesting AAV transduction itself limits hMSC chondrogenic potential to a certain extent. 
AAV-hIRAP transduction further inhibited hMSC chondrogenesis in a non-inflammatory 
environment. In fact, AAV-hIRAP transduction was only beneficial compared to other two 
groups in the presence of IL-1β. AAV-TGF-β1 transduction, on the other hand, rescued the AAV 
inhibition of chondrogenesis to some extent in both non-inflammatory and inflammatory 
environments. Although a direct comparison between hIRAP and TGF-β1 groups is not feasible 
since the two studies were done on separate trials, the mean fold value comparison suggests that 
the AAV-TGF-β1 transduced hMSCs performed better than the AAV-hIRAP transduced hMSCs.  
One of the limitations of pellet area measurement analysis is that area is a two-
dimensional measure of a three-dimensional hMSC chondrogenic pellet. However, the area 
measurement is a convenient and widely used parameter to evaluate chondrogenesis outcome 
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(57). As well, a separate trial that compared pellet areas to pellet wet weights showed significant 
correlation between the two measures (r = .955, p < .001; Data not shown).  
Histological and biochemical analysis of GAG contents of hMSC chondrogenic pellets 
further support the pellet area findings. Positive/red staining on Safranin O-Fast green stain 
indicate cartilageneous ECM development and hence an indicator of chondrogenesis (57). While 
all the hMSC pellets from the non-inflammatory cytokine stimulated environment showed 
positive Safrainin O-Fast green staining, the AAV-GFP and AAV-hIRAP transduced pellets had 
much less red staining than the untransduced control pellet. Among the pellets that were 
stimulated with IL-1β, AAV-hIRAP transduced pellet had the reddest staining. This general 
pattern was true for the GAG content quantification as well, with AAV-hIRAP pellets 
performing worst in non-inflammatory environment but best in the inflammatory environment. 
Of note, the inhibitory effect of AAV-GFP transduction on chondrogenesis compared to 
untransduced control was no longer appreciable in GAG content measurement.  
 The effect of hIRAP on hMSC chondrogenesis is unique in that it exerts inhibitory effects 
on chondrogenic differentiation in normal settings but protective effects in an inflammatory 
environment. A disease-regulated transgene expression system in this case would be beneficial 
with added measures of safety. A number of studies have investigated the development and 
characterization of the inflammation-inducible transgene promoters (177-179). These systems 
would allow expression of IRAP only when it is needed to exert protective effects while limiting 
its inhibitory effect on chondrogenesis. 
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6.5 CONCLUSIONS 
In conclusion, this study supports the use of AAV-mediated gene therapy to enhance the 
chondrogenic potential of hMSCs, and shows that anti-inflammatory molecules like IRAP and 
TGF-β1 blunts the cytokine-mediated inhibition of hMSC chondrogenesis. Use of this AAV gene 
therapy strategy to achieve localized and sustained expression of therapeutic factors from MSC 
pellets itself has a great promise for cartilage tissue engineering. The study also highlights the 
importance of adding the catabolic mediator inhibition in the strategy for MSC chondrogenesis. 
These results have implications for therapy design in terms of the choice of anti-inflammatory 
molecule, as well as the control of transgene expression. Overall, AAV is a promising gene 
transfer vehicle to deliver anti-catabolic bioactive molecules to hMSCs undergoing chondrogenic 
differentiation and its application to improve hMSC-mediated articular cartilage restoration 
should be further investigated. 
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7.0  OVERALL CONCLUSIONS 
Osteoarthritis (OA) affects nearly 27 million people (5) and costs almost $128 billion per year in 
medical care and indirect expenses in the US alone (79). However, despite its prevalence and 
morbidity, effective disease modifying treatments are still lacking. Articular cartilage has poor 
regenerative potential. Therefore, strategies to improve cartilage regeneration have a strong 
potential to reduce the disease burden of OA. In vitro and in vivo studies support the use of 
mesenchymal stem cells (MSCs) to improve cartilage regeneration. A tissue engineering 
approach, with the use of mesenchymal stem cells, bioscaffolds, and growth factors, is a 
promising therapeutic strategy against articular joint pathologies. However, successful intra-
articular delivery of therapeutic factors is limited due to their short half-lives, costly purification 
process, and need to administer supra-physiological doses and/or multiple delivery interventions. 
Adeno-associated viruses (AAVs) are a novel vector construct for gene therapy strategies that 
would allow the production of therapeutic proteins in situ. Here, we investigated various AAV-
administration approaches and therapeutic genes to test the central hypothesis that modulation of 
various anabolic and catabolic factors involved in MSC chondrogenesis via AAV will enhance 
the outcomes of joint restoration. 
In the first study presented in Chapter 2, AAV2 was delivered by a single intra-articular 
injection to an intact rat knee joint. This lead to persistent and stable transgene expression mainly 
in the intra-articular soft tissues, with limited expression in chondrocytes. Oral administration of 
 110 
doxycycline following an intra-articular injection of an inducible AAV2 vector permitted 
external regulation of in vivo transgene expression. This regulation was possible not only 
immediately after AAV injection, but also a year later.  
As intact joints are unlikely to require AAV intervention, characterization of AAV-
mediated transgene expression in joint injury models was presented in a follow up study in 
Chapter 3. AAV transgene expression was again localized to the intra-articular soft tissues of the 
uninjured joints as well as the injured joints when AAV was injected pre-injury. On the other 
hand, AAV transduced few articular chondrocytes within the cartilage matrix when injected 
following injuries, as the cartilage matrix injury may have facilitated entry of more AAV into the 
cartilage. These data supports use of AAV therapy in injured joints for cartilage repair/protection. 
Different localization of transgene expression can further be used to tailor joint restoration 
strategies. The post-injury AAV injection method can be used for genes that need to directly 
target articular chondrocytes or cartilage repair cells. Alternatively, pre-injury AAV injection 
method can be beneficial for delivery of gene that to soft-tissues, from which the bioactive 
molecules would be secreted at high levels to act upon the articular cartilage.  
For both studies in intact and injured joints, external control of intra-articular transgene 
expression was achieved using oral doxycycline. This greatly adds to the clinical utility of AAV 
as a treatment strategy for joint diseases. Doxycycline was further characterized for its effect on 
MSC chondrogenesis and cartilage repair in Chapter 4. There was a significant inhibition of 
MMP-13 expression in hMSC chondrogenic pellets cultured in the presence of doxycycline, 
leading to larger pellet size due to increased collagen-II retention. Oral administration of 
doxycycline in rats with osteochondral defects also lead to downregulation of MMP-13 
expression and gross improvement of the cartilage repair tissues. Therefore, doxycycline can not 
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only be used as an inductive agent for external control of AAV-mediated transgene expression, it 
can also exert intrinsic beneficial effect on cartilage repair.  
In the next part of the study in Chapter 5, we investigated and optimized fibrin glue (FG) 
as a potential AAV-releasing bioscaffold for in situ gene delivery. Diluted FG scaffolds had 
larger pores and thinner fibers, with enhanced release of AAV particles. More AAV was released 
from diluted FGs, which in turn transduced more target cells. With respect to cartilage tissue 
engineering applications, AAV-TGF-β1 from diluted FG released and transduced more hMSCs, 
which produced more bioactive TGF-β1, and resulted in higher upregulation of cartilage-specific 
genes than AAV-TGF-β1 from undiluted FG. Hence, implantation of bioactive AAV-embedded 
dilute FG scaffolds has stronger potential to improve articular cartilage regeneration.  
As the final part of the study, presented in Chapter 6, two bioactive therapeutic AAVs 
were explored for their potential to enhance hMSC chondrogenic differentiation in an 
environment that mimics the in vivo cartilage repair setting. AAV-IRAP transduction of hMSCs 
successfully blunted the inflammatory cytokine-mediated inhibition of hMSC chondrogenesis. 
However, AAV-TGF-β1 transduction of hMSCs did not result in successful chondrogenesis. The 
study also highlighted that a therapeutic molecule may exert different effects depending on the 
inflammatory status of the chondrogenic environment. AAV-IRAP-transduced pellets performed 
the best in an inflammatory setting; however, they performed the worst in non-inflammatory 
control environment.  
Instead of focusing on optimizing individual components of tissue engineering strategy, 
the fundamental focus of the current study was the potential for clinical translation. Therefore, 
we explored molecules, scaffolds, and cells that are already Food and Drug Administration 
(FDA)-approved, in clinical trials, or in clinical practice (54, 180). Thus, we hope our studies on 
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AAV serotype 2, doxycycline, FG, TGF-β1 and IRAP, can accelerate the transition of basic 
science research into human clinical applications.     
In conclusion, various aspects of AAV-mediated joint restoration approaches were 
investigated, from characterization of AAV delivery by direct injection or with the use of FG, to 
therapeutic applications with doxycycline, AAV-IRAP, and AAV-TGF-β1. These results support 
continued investigations of therapeutic potential of AAV for safe, localized, and controlled 
delivery of bioactive substances to promote joint restoration, which may delay/prevent the onset 
of debilitating osteoarthritis.  
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APPENDIX A 
CLINICAL AND BASIC SCIENCE OF CARTILAGE INJURY AND ARTHRITIS IN 
THE FOOTBALL (SOCCER) ATHLETE 
Joint injuries are very common in the athletic population, especially professional soccer players, 
with an incidence of 10 to 35.5 injuries per 1,000 hours. Most soccer-related joint injuries occur 
in the lower extremities, with 16% to 46% occurring in the knee and 17% to 40% occurring in 
the ankle. Because of the limited healing capacity of cartilage and other intra-articular soft tissue 
structures, such as anterior cruciate ligament (ACL) and meniscus, joint injuries often lead to the 
development of early disabling osteoarthritis. Osteoarthritis in soccer players is 5 to 12 times 
more frequent than in the general population, and diagnosed 4 to 5 years earlier. It remains a 
major cause of disability from this sport. This review focuses on the epidemiology of soccer-
related joint injuries and subsequent development of osteoarthritis in the hip, knee, and ankle 
joints. As well, two different pathways for pathogenesis are described: 1) primary osteoarthritis 
via direct trauma to the articular cartilage, and 2) secondary osteoarthritis that occurs indirectly 
through injury to the soft tissue structures that subsequently result in articular cartilage 
degeneration and loss. 
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A.1 SOCCER AND JOINT INJURIES 
Soccer is the most popular sport worldwide, with more than 240 million players overall, with 
200,000 being professional/elite athletes (181, 182). However, as it is a high-speed contact sport 
with the highest intensity of joint impact and torsional loading, soccer is a sport that puts 
maximal demands on the joints (183). There is an incidence of 10 to 35.5 injuries per 1,000 
training/playing hours (182, 184-186), with risk of injury during a match greater than that during 
training (187-190). This injury incidence is around 1,000 times higher than for high-risk 
industrial occupations (30, 190-193). Soccer, therefore, is estimated to be responsible for the 
majority of athletic injuries in Europe (185). Participation at a professional/elite level and/or 
more game hours can further increase the risk and severity of injuries 
(7, 29, 30, 181, 186, 187, 191, 194-199). Most soccer injuries occur in the lower extremities (52 
– 95%), with the knee (16 – 46%) and the ankle (17 – 40%) being most prevalent 
(181, 185, 189, 195-198, 200-205). The subsequent risk of early development of osteoarthritis 
(OA) is also expected to be high, and OA has been reported to be the major chronic injury 
suffered by professional soccer players (206).  
A.2 EPIDEMIOLOGY OF SOCCER AND OSTEOARTHRITIS 
The studies on OA and its relationship to soccer have been variable in terms of joint location, age 
groups, and outcome measures. Among former professional soccer players, 32% to 49% were 
medically diagnosed with OA (29, 193), with the knee being affected most frequently, followed 
by the ankle and hip (195). The prevalence of OA is greater in players who had retired due to 
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injury than those who had retired for other reasons (195). Soccer players had an increased odds 
ratio of 2.10 for hospital admissions, likely for total joint arthroplasty, for OA of the hip, knee, 
and ankle (29). Their mean age at first admission was also earlier at 56.2 years versus 61.2 years 
in controls. When the locations of the OA were separated, 8 incidences were for the hip, 5 for the 
knee, and 2 for the ankle. Hence, admissions for OA of the hip and knee were more common 
than for OA of the ankle. 
A.2.1 Ankle osteoarthritis in soccer 
oss of joint space and formation of new bone at the articular surface via 
radiography (207). 
A.2.2 Knee osteoarthritis in soccer 
Ankle sprains are common soccer injuries and are generally thought to be benign. However, 
studies report persistent signs and symptoms for months to years in 59% to 100% of injured 
soccer athletes (207-209). Soccer was also the sport that most frequently gave rise to ankle 
injuries that caused post-traumatic ankle arthritis (210), with one study quoting 33% of injured 
ankles developing radiographic signs of arthritis after 25 years (194). This risk of developing 
arthritis was greater than that compared to the non-injured soccer players and age-matched 
general population controls. On the other hand, another study reported only 1 1.6% overall 
incidence of ankle osteoarthrosis in soccer players, when the definition of ankle OA was strictly 
narrowed to be a l
Among former professional soccer players, the radiographic signs of knee OA in soccer players 
increased with age in a greater percentage than in the general public (211). Radiographic signs of 
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knee arthritis were present in 15.5% to 63% of injured knees (30, 194, 211, 212); however, the 
rate of clinical symptoms was significantly less. The prevalence of radiographic signs of knee 
OA was also greater among elite soccer players compared to controls and non-elite players (30). 
Thus, the authors concluded that soccer in associated with an increased risk of knee OA, 
especially at an elite level. Soccer players were also younger when they were diagnosed with 
knee OA. However, there was no difference in knee OA risk between the non-elite and controls 
when s
e knee OA among men 
aged be
soccer player group, despite the more severe radiological structural damages in the latter 
(205). 
A.2.3 Hip osteoarthritis in soccer 
occer players with known knee damage were excluded from the analysis. 
Among patients with radiographic signs of knee OA, soccer was one of the sports that 
was significantly related to knee OA among men (213). This increased risk of knee OA with 
soccer remained after adjusting for body mass index (BMI), heredity, smoking, and occupation, 
but not after adjusting for previous knee injuries. Similarly, when patients undergoing total knee 
replacement were examined, there was an increased relative risk of sever
tween 55 and 65 years who were highly exposed to soccer (214). 
On the other hand, some studies showed no difference in the frequency of radiograph-
confirmed knee OA between former elite soccer players and controls (205, 215). Paradoxically, 
subjects having symptomatic knee OA were more frequent in the control group than in the 
former 
In addition to the ankle and the knee, many studies report a higher incidence of hip OA in former 
soccer players compared to age-matched controls (191, 215, 216). The prevalence of hip OA 
between these two groups was significantly different, with an odds ratio of 10.2 (216). It was 
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also determined that hip OA in former elite soccer players was three times more common 
compared to non-elite players (191). Soccer players were diagnosed with hip OA at a younger 
age, similar to the knee OA findings. Among men who recently received a prosthesis due to 
severe idiopathic hip osteoarthrosis, there was an increased risk among men with medium and 
high exposure to soccer (11). Nonetheless, soccer was not one of the most hazardous sports, 
which included track and field sports and racket sports. 
A.2.4 Summary 
early 
development of OA in the lower extremities, and this risk is higher in professional players. 
A.3 PATHOGENESIS OF SOCCER-RELATED OSTEOARTHRITIS 
Studies have variable findings, primarily due to different methodologies used; the outcome 
definition and criteria were rarely consistent across studies. Structural outcomes, such as 
radiographic changes, do not correlate well with patient-relevant aspects, such as pain and 
function (17). However, long-term soccer training/playing seems to increase the risk for 
The most common soccer injuries are sprains and strains affecting mainly the ankle and knee 
joints. A single game of soccer has not been shown to directly result in increased cartilage 
breakdown products (217); however, soccer, may increase the risk for OA in two different ways: 
1) directly by high loading on the articular cartilage that leads to primary OA and 2) indirectly by 
damaging the extra-cartilage soft tissue structures within the joint that will subsequently lead to 
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joint instability and secondary OA (206). The intensity and duration of a sporting activity 
increase the occurrence of arthritic impairment (205). 
rogressive cartilage damage and ultimately lead to OA (205). 
Some s
sign and stimulator of deterioration of load-bearing cartilage function. Chondrocyte 
apoptosis rate in the human explants study also correlated with the GAG findings, with 
significantly higher apoptosis in the loaded (34%) versus control explants at 96 hours post-injury 
(219).  
A.3.1 Primary osteoarthritis 
The articular cartilage surface can be damaged through sports participation via a single or 
repetitive impact or torsional loadings. The hip and the knee are the two main locations that 
many develop OA due to traumatic joint loading (206, 218). Direct acute trauma with an 
osteochondral impact may induce p
tudies that reported an increased risk of former elite soccer players to develop hip OA 
also postulated that compression of the joint surface and sudden shock to the joints can cause 
cartilage degeneration (191, 216). 
Potential mechanisms for the rapid progression of OA after such an injury are extensively 
studied in both in vitro and in vivo settings, and studies have shown that matrix degradation, 
chondrocyte death, and/or abolishment of anabolic functions occur after impact to articular 
cartilage. Chondrocyte death leads to biochemical changes of the extracellular matrix and 
weakening of its biomechanical properties. In vitro studies on human cartilage explants have also 
shown significantly increased glycosaminoglycan (GAG) breakdown and release from the 
injured versus unloaded intact cartilages during 0 to 3 days post-injury (219, 220). Since the 
mechanical properties of articular cartilage are largely defined by the GAG content, GAG loss is 
both a 
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A.3.2 Secondary osteoarthritis 
Indirect cartilage injury and subsequent arthritis development due to joint instability induced by 
damaging the extra-cartilage soft tissue structures that leads to chronic joint injury is a common 
soccer-related pathological process for the knee and ankle joints. Pathologic changes in all joint 
components, not just the cartilage, are an integral part of OA. 
A.3.2.1  Ankle 
When the mechanism of injury was investigated, 49.3% to 55% of all ankle sprains occurred 
during athletic activity, with soccer being one of the most common athletic activities (210). Most 
ankle sprains involve the lateral ligament complex of the ankle joint (194, 208). Post-traumatic 
OA of the ankle accounts for more than 70% of ankle arthritis (210). The overall mean latency 
time for the development of ligamentous post-traumatic ankle OA is 34.3 years, with a range of 6 
to 57 years (210). There was a significant difference between the patients with a single severe 
ankle sprain and with recurrent ankle springs, with longer latency time with the latter group. 
A.3.2.2  Knee 
The knee anterior cruciate ligament (ACL) and menisci injuries are common in the general 
population and in soccer players. Studies report 24% to 40% and 21% to 31% of soccer injuries 
in the knee joint were ligamentous and meniscal injuries, respectively (29, 185, 192, 197, 200). 
Injuries to the ACL and menisci are believed to be the main reason for the increased risk of knee 
OA in soccer players (221). Both ACL and menisci injuries have been shown to be followed by 
arthritic changes of the knees (29). In addition to the initial high force that damages intra-
articular structures involved in the trauma (30), the ACL and menisci disruptions initiate a 
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cascade of pathogenic processes in the acute phase that can lead to the development of OA in 
itself (17). There are also findings of greatly increased concentrations of markers of cartilage 
matrix metabolism in joint fluid in connection with trauma (222). In addition to acute effects, the 
lack of a functionally normal ACL or menisci leads to chronic changes in the static and dynamic 
loading of the knee and increases forces on the cartilage and other joint structures. 
A.3.2.2.1  ACL injury and osteoarthritis in soccer players 
The ACL is the most commonly disrupted knee ligament (17, 222). Nearly 40% of all soccer-
related knee injuries are ACL injuries (222), and a risk increase has been estimated at 100 to 
1,000 in professional soccer (195, 223). A complete ACL tear usually causes a long layoff from 
soccer and may even end the athletic career (224). Soccer athletes sustain more ACL injuries 
than basketball players when compared by sex (225). Nonetheless, isolated ACL ruptures are 
uncommon due to the high impact of the trauma, and it is often associated with injuries to other 
intra-articular structures. A meniscal injury most frequently accompanies an ACL injury: it is 
associated with 50% to 75% of all acute ACL cases (183).  
 The mechanism responsible for cartilage degeneration following ACL injury is unclear. 
Biomechanical instability of the joint does not appear to be the only factor, and additional 
biochemical factors, such as inflammatory cytokines from synovitis, are also important. Dogs 
that underwent surgical transection of the ACL had significant elevation of cartilage breakdown 
products, collagenase-generated cleavage epitope of type II collagen, and cross-linked peptides 
from the C-telopeptide domain of type II collagen in their joint fluid at 3 and 12 weeks post-
operatively (226). The long-term clinical consequences of ACL rupture in soccer players have 
also been well studied: soccer players with an ACL tear are also more likely to develop knee OA 
than those players with intact ACL (183). At 12 to 14 years after an ACL tear, 75% of soccer 
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athletes had significant symptoms, and 41% to 77% had radiographic knee OA (221, 227). 
Additional meniscus injury requiring surgery was the most significant factor that may strongly 
influence the long-term symptoms and OA prevalence after ACL injury (227). 
 The effect of ACL reconstruction on the subsequent development of knee OA has been 
controversial. Most studies report that the increased risk of development of OA following ACL 
injury remains unchanged regardless of the surgical ACL repair status (17, 221). When the 
clinical and radiographic outcomes of surgical repair or non-surgical ACL treatments were 
compared, it was reported that an ACL reconstruction itself did not reduce the risk of OA (32). 
ACL repair also did not increase the subjective symptomatic scores; however, it did decrease 
instability problems. In conclusion, although ACL reconstruction may facilitate restoring the 
kinematics of the joint, it does not make the knee normal (17). There is a lack of evidence to 
support a protective role of ACL reconstruction surgery against OA, both in athletes and in the 
general population. Hence, the ACL-injured knee, whether it is repaired or not, will be subjected 
to abnormal loading over time, significantly increasing the risk of OA. 
A.3.2.2.2  Meniscus injury and osteoarthritis in soccer players 
Sports-related acute injuries to the menisci are common; however, the incidence of meniscus 
injuries in soccer is not as clearly described as the incidence of ACL injuries (206). ACL injuries, 
which are common in soccer, are associated with a meniscus tear in up to 75% of cases (183). As 
well, some investigators say that soccer is first and foremost a hazard to the menisci since a blow 
to the knee while weightbearing is more likely to cause damage to the menisci than to the 
ligaments (197). In a study on former elite soccer players compared to age-matched controls, 
14% of the former players had meniscal injuries resulting in meniscectomy versus 2% in the 
control group (30). In another study, of the 33% of sports-related meniscal injuries resulting in 
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meniscectomy, 5% were soccer-related (228). Finally, in a study comparing meniscal tear 
patients to controls, meniscal tear and knee cartilage injuries were strongly associated with 
participation in sports, especially soccer, during the 12-months preceding the onset of symptoms 
(229).  
One of the treatments available for meniscal injury is total meniscectomy. However, this 
results in increased load stresses on the underlying articular cartilage and development of knee 
OA. The degree of OA has also been shown to be directly proportional to the amount of 
meniscus removed (230). Hence, meniscal tears are a potent risk factor for the development of 
knee OA, regardless of the surgical status (192). However, as stressed above, meniscus lesion 
combined with ACL tear are associated with the greatest risk of OA development (194). In 
comparison to ACL patients, patients with isolated meniscus injury were about 10 years older 
when they had a comparable stage of OA (222).  
About 50% of meniscal injury patients with a partial or total meniscectomy have both 
symptomatic and radiographic signs of OA of the knee 5 to 20 years after injury (222, 230-233). 
This represents an odds ratio of about 10 (17) and relative risk of 14.0 (233) for the presence of 
the more advanced radiographic changes compared with an age- and sex-matched control group 
without known knee injury. Among former soccer players, all players who had a meniscectomy 
presented radiographic signs of OA 10 to 20 years after surgery, compared to 40% in players 
who had not undergone meniscectomy (211). 
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A.4 CONLUSIONS 
Joint injuries, including ligament, meniscal, and cartilage injuries, are common in sports, 
especially in soccer. These soccer-related injuries are most common in the lower extremities, 
involving the knee, hip, and ankle. Subsequent cartilage damage of the affected joints is due to 
primary joint impact and/or secondary to the extra-cartilage soft tissue injuries that lead to joint 
instability and degeneration of articular cartilage. Although primary osteoarthritis from joint 
impact is frequently responsible for the development of osteoarthritis in the hip and knee, 
secondary arthritis associated with ligamentous injury occurs primarily in the ankle and knee. 
The anterior cruciate ligament and menisci are the two intra-articular soft tissues that most often 
get injured during soccer and also play a critical role in OA development. Unfortunately, 
currently available treatment strategies, surgical or conservative, are inadequate to prevent the 
development of OA. Hence, there is a strong need for the development of molecular, biological, 
and mechanical interventions to delay or prevent the onset of post-injury OA. 
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